<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Landscape of germline BRCA1&#x2F;BRCA2 variants in breast and ovarian cancer in Peru</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":2.7904,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVUUU9XAVFTCAUMHQNACg4=","queueTime":0,"ttGuid":"0f9b16de767666ab"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full">
<meta property="description" name="description" content="There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conduc...">
<meta property="og:title" name="title" content="Frontiers | Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru">
<meta property="og:description" name="description" content="There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conduc...">
<meta name="keywords" content="breast cancer,ovarian cancer,BRCA1,BRCA2,germline mutation">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="13">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2023.1227864">
<meta name="citation_firstpage" content="1227864">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru">
<meta name="citation_keywords" content="breast cancer; ovarian cancer; BRCA1; BRCA2; germline mutation">
<meta name="citation_abstract" content="There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors. The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar.. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied. We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G>T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c. 8023A>G (n=6,  16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG,  n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C>G (n=2), and for BRCA2, c.5465A>T (n=4), c.3101T>C (n=3), c.205C>A and c.437T>C (n=2). We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A>G. We found that BRCA2 c.8023A>G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2023/07/27">
<meta name="citation_publication_date" content="2023/08/17">
<meta name="citation_author" content="Ferreyra, Yomali ">
<meta name="citation_author_institution" content="Departamento de Bioingeniera, Universidad de Ingenieria y Tecnologa, Peru">
<meta name="citation_author" content="Rosas, Gina ">
<meta name="citation_author_institution" content="Departamento de Patologa, Insituto Nacional de Enfermedades Neoplsicas, Peru">
<meta name="citation_author" content="Cock-Rada, Alicia M. ">
<meta name="citation_author_institution" content="Departmento de Oncologa Mdica, Instituto de Cancerologa Las Amricas - Auna, Colombia">
<meta name="citation_author" content="Araujo, Jhajaira ">
<meta name="citation_author_institution" content="Centro de Investigacin Bsicas y traslacional, Peru">
<meta name="citation_author" content="Bravo, Leny ">
<meta name="citation_author_institution" content="Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Peru">
<meta name="citation_author" content="Doimi, Franco ">
<meta name="citation_author_institution" content="Oncogenomics, Auna, Peru">
<meta name="citation_author" content="Casas, Jhoysi ">
<meta name="citation_author_institution" content="Oncogenomics, Auna, Peru">
<meta name="citation_author" content="Clavo, Mara de los ngeles ">
<meta name="citation_author_institution" content="Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga, Peru">
<meta name="citation_author" content="Pinto, Joseph A. ">
<meta name="citation_author_institution" content="Centro de Investigacin Bsicas y traslacional, Peru">
<meta name="citation_author" content="Belmar-Lpez, Carolina ">
<meta name="citation_author_institution" content="Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Peru">
<meta name="dc.identifier" content="doi:10.3389/fonc.2023.1227864">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru","author":[{"@type":"Person","name":"Yomali Ferreyra","affiliation":["Departamento de Bioingeniera, Universidad de Ingenieria y Tecnologa, Peru"]},{"@type":"Person","name":"Gina Rosas","affiliation":["Departamento de Patologa, Insituto Nacional de Enfermedades Neoplsicas, Peru"]},{"@type":"Person","name":"Alicia M. Cock-Rada","affiliation":["Departmento de Oncologa Mdica, Instituto de Cancerologa Las Amricas - Auna, Colombia"]},{"@type":"Person","name":"Jhajaira Araujo","affiliation":["Centro de Investigacin Bsicas y traslacional, Peru"]},{"@type":"Person","name":"Leny Bravo","affiliation":["Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Peru"]},{"@type":"Person","name":"Franco Doimi","affiliation":["Oncogenomics, Auna, Peru"]},{"@type":"Person","name":"Jhoysi Casas","affiliation":["Oncogenomics, Auna, Peru"]},{"@type":"Person","name":"Mara de los ngeles Clavo","affiliation":["Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga, Peru"]},{"@type":"Person","name":"Joseph A. Pinto","affiliation":["Centro de Investigacin Bsicas y traslacional, Peru"]},{"@type":"Person","name":"Carolina Belmar-Lpez","affiliation":["Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Peru","Oncogenomics, Auna, Peru"]}],"datePublished":"2023-08-17","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2023","isPartOf":{"@type":"PublicationVolume","volumeNumber":"13","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2023.1227864"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 17 August 2023</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Breast Cancer</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 13 - 2023 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2023.1227864">https://doi.org/10.3389/fonc.2023.1227864</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">BRCA mutations and Homologous Recombination Deficiency (HRD) testing in ovarian cancer</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 8 articles" href="https://www.frontiersin.org/research-topics/54586/brca-mutations-and-homologous-recombination-deficiency-hrd-testing-in-ovarian-cancer/magazine" target="_self" data-event="customLink-linkType-a_viewAll8Articles"><span>View all 8 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Landscape of germline <i>BRCA1/BRCA2</i> variants in breast and ovarian cancer in Peru</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2212695" class="user-id-2212695"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2212695/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Yomali Ferreyra">Yomali Ferreyra</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Gina Rosas" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Gina Rosas<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Alicia M. Cock-Rada" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Alicia M. Cock-Rada<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jhajaira Araujo" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jhajaira Araujo<sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Leny Bravo" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Leny Bravo<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Franco Doimi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Franco Doimi<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jhoysi Casas" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jhoysi Casas<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Mar&#xed;a de los &#xc;ngeles Clavo" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Mar&#xed;a de los &#xc1;ngeles Clavo<sup>7</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/519797" class="user-id-519797"><img class="pr5" src="https://loop.frontiersin.org/images/profile/519797/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Joseph A. Pinto*">Joseph A. Pinto</a><sup>4*</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1513359" class="user-id-1513359"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1513359/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Carolina Belmar-L&#xf;pez,">Carolina Belmar-L&#xf3;pez</a><sup>5,6</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Departamento de Bioingenier&#xed;a, Universidad de Ingenieria y Tecnolog&#xed;a, Lima, Peru</li><li><span><sup>2</sup></span>Departamento de Patolog&#xed;a, Insituto Nacional de Enfermedades Neopl&#xe1;sicas, Lima, Peru</li><li><span><sup>3</sup></span>Departmento de Oncolog&#xed;a M&#xe9;dica, Instituto de Cancerolog&#xed;a Las Am&#xe9;ricas - Auna, Medell&#xed;n, Colombia</li><li><span><sup>4</sup></span>Centro de Investigaci&#xf3;n B&#xe1;sicas y traslacional, Auna Ideas, Lima, Peru</li><li><span><sup>5</sup></span>Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Ica, Peru</li><li><span><sup>6</sup></span>Oncogenomics, Auna, Lima, Peru</li><li><span><sup>7</sup></span>Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga, Ica, Peru</li></ul><p><b>Background:</b> There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate&#x2013;ribose) polymerase (PARP) inhibitors.</p><p><b>Methods:</b> The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied. </p><p><b>Results:</b> We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G&gt;T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c.8023A&gt;G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C&gt;G (n=2), and for BRCA2, c.5465A&gt;T (n=4), c.3101T&gt;C (n=3), c.205C&gt;A and c.437T&gt;C (n=2). </p><p><b>Conclusion:</b> We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A&gt;G. We found that BRCA2 c.8023A&gt;G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.2%.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Background</h2><p class="mb15">Breast and ovarian cancer are highly prevalent malignancies in Latin America, where more than 50 thousand patients die yearly from these pathologies. It is estimated that 5-10% of breast cancer (BC) and 10-15% of ovarian cancer (OC) are attributed to hereditary breast and ovarian cancer (HBOC). Mutations in the <i>BRCA1</i> and <i>BRCA2</i> genes are the best-known genetic risk factors for breast and ovarian cancer (<a href="#B1">1</a>&#x2013;<a href="#B3">3</a>).</p><p class="mb15">Detecting <i>BRCA1/2</i> mutations allows crucial and challenging decisions regarding cancer prevention or risk reduction, early detection and pharmacological management. Germline <i>BRCA1/2</i> variants cause hereditary breast and ovarian cancer syndrome and confer a lifetime risk of 38-87% of developing breast cancer in women and 16.5-63% of developing ovarian cancer (<a href="#B4">4</a>). Germline <i>BRCA1/2</i> mutations are present in approximately 5% of all breast patients and 15% of all ovarian cancer patients (<a href="#B5">5</a>, <a href="#B6">6</a>). Breast tumors with <i>BRCA1/2</i> mutation carriers are more frequently HER2 negative, and triple-negative tumors (TNBC) account for approximately 68% of <i>BRCA1</i> tumors (<a href="#B7">7</a>). High-grade serous ovarian cancers are more commonly associated with <i>BRCA1/2</i> mutations (<a href="#B8">8</a>).</p><p class="mb15"><i>BRCA1/2</i> are tumor suppressor genes that participate in the homologous recombination repair of double-strand DNA damage. <i>BRCA1/2</i> defective cells are more sensitive to Poly(ADP-ribose) polymerase (PARP), an enzyme involved in base excision repair, a vital component of single-strand break repair (SSB). PARP inhibitors can increase SSB, which are converted to double-strand DNA breaks (DSBs) during replication. In defective <i>BRCA1/2</i> cells, these DSBs are not effectively repaired, leading to chromosomal instability, cell cycle arrest, and subsequent apoptosis, a mechanism known as synthetic lethality (<a href="#B9">9</a>)</p><p class="mb15">Several PARP inhibitors have been developed to treat patients with breast, ovarian, pancreatic, and prostate cancer with <i>BRCA1/2</i> mutations. OlympiAD, a phase III randomized, controlled, open-label study trial, compared Olaparib, a PARP inhibitor, with non-platinum chemotherapy (CT) in metastatic breast cancer patients with germline <i>BRCA</i>1/2 mutations. Progression-free survival (PFS) was higher in patients receiving Olaparib than in those receiving CT (7.0 vs 2.2 months). The hazard ratio (HR) for disease progression or death was 0.58 (95% CI 0.43-0.80: P&lt; 0.001). The response rate was 59.9% in the Olaparib group and 28.8% in the CT group. An improvement in PFS was observed in all subtypes and was higher in TNBC patients (<a href="#B10">10</a>).</p><p class="mb15">The randomized phase III trial, EMBRACA, compared another PARP inhibitor, Talazoparib, with single-agent CT in patients with advanced breast cancer with <i>BRCA1/2</i> mutations. The median PFS was longer in the Talazoparib group than in the control group (8.6 months [95% CI, 7.2-9.3] vs 5.6 months [95% CI, 4.2-6.7]; HR=0.54 [95% CI 0.41-0.71; P &lt; 0.001] for disease progression or death. Based on these two trials, the FDA approved Olaparib and Talozaparib for HER2-negative patients with <i>BRCA1/2</i> mutations, and the NCCN guidelines recommend testing for <i>BRCA1/2</i> mutations in all patients with TNBC or metastatic breast cancer to identify candidates for PARP inhibitor therapy (<a href="#B11">11</a>).</p><p class="mb15">For ovarian cancer, germline testing for <i>BRCA</i>1/2 is informative for selecting patients for PARP inhibitor therapy. Around 50% of ovarian tumors are homologous recombination deficient (HRD) and 20% are associated with <i>BRCA1/2</i> mutations, germline (14%) or somatic (6%) (<a href="#B6">6</a>). PARP inhibitor treatment is recommended for maintenance therapy for stage II-IV disease or persistent or recurrent disease in BRCA<i>1/2</i> mutated ovarian cancer (<a href="#B12">12</a>). The SOLO-1 phase III trial showed an improvement in 3-year PFS with Olaparib versus Placebo as maintenance therapy for patients with a germline <i>variant BRCA1/2</i>, who had a complete or partial response (CR/PR) after platinum-based first-line chemotherapy (60% vs. 27%; P&lt;0.0001); HR=0.30 [95% CI, 0.23-0.41] (<a href="#B13">13</a>). Other phase III studies with PARP inhibitor, PAOLA-1: Olaparib + Bevacizumab versus Placebo + Bevacizumab for maintenance therapy for patients with advanced disease who had CR/PR after platinum-based first-line chemotherapy, or PRIMA: Niraparib versus Placebo as maintenance therapy for patients with CR/PR after platinum first-line chemotherapy showed a notable improvement in median PFS, especially in patients with a germline <i>BRCA</i>1/2 mutation or HRD (22.1 vs 16.6 months and 21.9 months vs 10.4 months, respectively) (<a href="#B14">14</a>, <a href="#B15">15</a>).</p><p class="mb15">There is increasing information on the molecular epidemiology of <i>BRCA1/2</i> genes in Latin America and several founder mutations have been identified (<a href="#B16">16</a>). Founder mutations in Latin America have been reported in Mexico (<i>BRCA1</i> del exons 9-12), Brazil (<i>BRCA1</i> 5382insC and <i>BRCA2</i> c.156_157insAlu), and Colombia (<i>BRCA1</i> 3450del4, A1708E and <i>BRCA2</i> 3034del4) (<a href="#B17">17</a>).</p><p class="mb0">Unfortunately, there is a gap in information about the genetic epidemiology of breast and ovarian cancers in Peru. A limited number of publications describe the frequency of <i>BRCA1</i> and <i>BRCA2</i> mutations in Peru with studies with small sample sizes and in a particular group of patients (<a href="#B18">18</a>). Here, we describe the frequency and spectrum of genetic variants (pathogenic/likely pathogenic P/LP and VUS) in <i>the BRCA1/2</i> genes in patients with BC and/or OC, profiled during 2019-2021 in a reference laboratory in Peru, for the identification of PARP inhibitor candidates.</p><a id="h3" name="h3"></a><h2>Methods</h2><h3>Study population</h3><p class="mb0">The study included all BC and OC patients, referred to Oncogenomics Laboratory (Lima, Peru) from 2019 to 2021, to identify candidates for PARP inhibitors treatment. The histological tumor types, hormone receptor and human epidermal growth factor receptor 2 (HER2) statuses were recorded.</p><h3><i>BRCA1/2</i> mutation screening</h3><p class="mb0">Peripheral blood samples were taken to assess mutations in <i>the BRCA1/2</i> genes. DNA was extracted using the ReliaPrep Blood gDNA Miniprep System or the ReliaPrep FFPE gDNA Miniprep System (Promega, Madison, USA) according to the manufacturer&#x2019;s protocol. DNA concentration was determined by fluorometric quantitation using a Qubit 4.0 fluorimeter with Qubit dsDNA HS ASSAY KIT (Invitrogen, USA). The panel targets single nucleotide variants (SNVs) and insertion/deletions (indels) in all exonic regions of the <i>BRCA1</i> and <i>BRCA2</i> genes and flanking intronic sequences. A commercial reference standard, Horizon Quantitative Multiplex Reference Standard HD810 was tested to validate the performance of NGS that detect mutations. Libraries were prepared using the Ampliseq <i>BRCA</i> Panel and Ampliseq Library PLUS (Illumina, San Diego, USA) following the manufacturer&#x2019;s protocol without modifications using 10 ng of input DNA per sample. The multiplex polymerase chain reaction (PCR) was performed in 18 cycles. Sequencing adapters with unique indexes (AmpliSeq CD Indexes Set A for Illumina) were ligated to the amplification products and purified using Agencourt AmpureXP beads (Beckman Coulter, CA, USA) according to the manufacturer&#x2019;s instructions. Libraries with 2nM molarities were subjected to clustering using a standard flow cell and sequenced on the Illumina MiSeq platform using the MiSeq Reagent Micro Kit v2 (300 cycles). Raw data were processed automatically in the BaseSpace Sequence Hub (Illumina) and aligned with the hg19 reference genome. An average of 95.7% (91.7&#x2013; 99.8%) on-target reads, 96.6% (94.7 &#x2013; 98.6%) read uniformity and 50X average coverage per sample were obtained.</p><h3>Mutation nomenclature and classification</h3><p class="mb15">BaseSpace Variant Interpreter (Illumina) annotated and interpreted genetic variants. Genetic variants were annotated under the nomenclature of the Human Genome Variation Society (HGVS). Interpretation was made using the single nucleotide polymorphism database (dbSNP), breast cancer information core (BIC) and Clinvar database. The Integrative Genomics Viewer was applied to visualize the variants. All identified variants were checked with Varsome (Saphetor, Swiss).</p><p class="mb0">Interpreting the pathogenicity of the variants followed the latest recommendations of the American College of Medical Genetics (ACMG) and ClinVar. In cases of conflicting interpretations of pathogenicty (classified as pathogenic by at least one database and benign, likely benign, or VUS by others) between ACMG and ClinVar, ACMG classification was used. All new variants (missense, in frame and splicing) not yet reported in the databases consulted, were also considered VUS. Benign variants were not reported.</p><h3>Statistical analysis</h3><p class="mb0">We conducted a descriptive analysis. The frequency of variants identified in the <i>BRCA1/2</i> genes was calculated using RStudio. Packages such as <i>sf, ggplot2</i> and <i>ggrepel</i> were installed to obtain geographical maps of Peru, to observe the distribution of pathogenic variants according to the place of birth of the patients.</p><a id="h4" name="h4"></a><h2>Results</h2><h3>General characteristics of patients</h3><p class="mb0">A total of 525 patients were included in this study (143 with BC and 382 with OC). Most of the patients were born in metropolitan Lima (58.1%), followed by patients from the coast (excluding metropolitan Lima, 28.0%), highlands (11.6%) and jungle (2.1%). Regarding the clinical characteristics of BC patients, 21.7% (n=31) had HER2-negative and hormone receptor positive tumors, while 78.3% (n=112) of the patients had HER2-negative and hormone receptor negative tumors (TNBC). Most of the OC (90.8%) were high-grade serous carcinomas. The frequency of clinical stage III was 33.6% and 50%, and clinical stage IV was 66.4% and 50% for BC and OC, respectively (<a href="#T1">Table 1</a>). The prevalence of patients with P/LP germline variants in <i>BRCA1/2</i> was 19.0% (n=100/525). No patient had more than one P/LP variant. The percentage of BC patients who carried germline <i>BRCA1/2</i> P/LP variants was 14.7% (n=21/143) with 61.9% (n=13/21) of them carrying variants in <i>BRCA1</i> and 38.1% (n=8/21) in <i>BRCA2</i> (<a href="#f1">Figure&#xa0;1</a>). In total, 81% (n=17/21) of patients with <i>BRCA1/2</i> P/LP variants were TNBC and 19.1% (n=4/21) were positive for hormone receptors. Furthermore, 38.1% (n=8/21) were reported in clinical stage III and 61.9% (n=13/21) in clinical stage IV. Although we had no information about their age at the time of diagnosis, the mean age at molecular diagnosis was 48.63 years (range: 30-74 years).On the other hand, 20.7%(n=79/382) of OC patients had germline <i>BRCA1/2</i> P/LP variants with 64.8% (n=51/79) of them in <i>BRCA1</i> and 35.44% (n=28/79) in <i>BRCA2</i>. Regarding the histological subtypes of <i>BRCA1/2</i> OC patients, it was observed that 91.1% (n=72/79) were characterized by high-grade serous carcinoma, followed by endometrioid carcinoma (n=5/79, 6.3%) and clear cell carcinoma (n=2/79, 2.53%). The clinical stages were distributed in 49.4% (n=39/79) stage III and 50.6% (n=40/79) stage IV. Furthermore, only 77 patients had their age at molecular diagnosis available, so the mean age was 54.36 years (range: 34-77).</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" name="table&#xa0;1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;1</b> Clinicopathological characteristics of the general population.</p></div><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;1</b> Flowchart showing results and characteristics of patients with breast and ovarian cancer included in this study. P/LP, Pathogenic/likely pathogenic.</p></div><div class="DottedLine"></div><h3>Germline <i>BRCA1</i> pathogenic/likely pathogenic variants</h3><p class="mb0">The study identified 33 different P/LP germline variants in <i>BRCA1</i> gene in 64 patients, finding 20.3% (n=13/64) in BC and 79.9% (n=51/64) in OC. The most frequent variants in <i>BRCA1</i> were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G&gt;T and c.815 _824dupAGCCATGTGG (n=5, 7.81%) (<a href="#T2">Table&#xa0;2</a>). Most variants were previously reported, except <i>BRCA1</i> c.2344dupA (n=2, 2.74%), which was not reported in any database. These patients were born in Lima and Arequipa.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" name="table&#xa0;2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;2</b> Pathogenic/likely pathogenic germline <i>BRCA1</i> variants found in our study.</p></div><div class="DottedLine"></div><p class="mb0">Furthermore, <i>BRCA1</i> P/LP variants were observed mainly in exon 10 (n=20/33), exon 19 (n = 3/33), and exon 2 and 4 (n=2/33). Most of the P/LP variants were missense (n=13/33) and in frame deletion variants (n=12/33), followed by frame insertions (n=6/33) and stop gained variants (n=1/33) (<a href="#T2">Table&#xa0;2</a>). There was only one case with a large deletion, specifically a deletion of exon 11 (n=1/33). Patients with P/LP variants in the <i>BRCA1</i> gene were born primarily in Metropolitan Lima (n=37/64), the coast (n=21/64) and the highlands (n=6/64). The most frequent P/LP variants in <i>BRCA1</i>, c.2105dupT (n=11) and c.68_69delAG (n=5) were found predominantly in patients born in Metropolitan Lima (<a href="#f2">Figure&#xa0;2A</a>). The position of P/LP variants in relation to the Brca1 protein is shown in <a href="#f3">Figure&#xa0;3A</a>.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;2</b> Pathogenic/likely pathogenic germline <i>BRCA1/2</i> variants according to the place of birth <b>(A)</b> Germline <i>BRCA1</i> LP/P variants <b>(B)</b> Germline <i>BRCA2</i> LP/P variants.</p></div><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;3</b> Maps presenting counts of pathogenic and likely pathogenic variants sites in <b>(A)</b> Brca1 and <b>(B)</b> Brca2 proteins.</p></div><div class="DottedLine"></div><h3>Germline <i>BRCA2</i> pathogenic/likely pathogenic variants</h3><p class="mb0">We found 22 different P/LP variants in <i>BRCA2</i> among 36 patients, 22.2% (n=8/36) in BC and 77.8% (n=28/36) in OC. The most frequent mutations in <i>BRCA2</i> were c.8023A&gt;G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%) (<a href="#T3">Table&#xa0;3</a>). Likewise, most of the <i>BRCA2</i> P/LP variants were found only in OC patients (n=14/22, 63.63%), followed by both OC and BC patients (n=4/22, 18.18%) and only BC patients (n=4/22, 18.18%). Furthermore, <i>BRCA2</i> variants were mainly reported in exon 11 (n=9/22, 40.91%), predominantly inframe deletions (n=10/22), followed by inframe insertions (n=6/22) and missense variants (n=5/22) (<a href="#T3">Table&#xa0;3</a>). Only one large deletion was identified in exon 10. Patients with P/LP variations in <i>BRCA2</i> were born in Metropolitan Lima (n = 24/36), on the coast (n=9/36) and in the highlands (n=3/36) (<a href="#f2">Figure&#xa0;2B</a>). The position of P/LP variants in relation to the Brca<i>2</i> protein is shown in <a href="#f3">Figure&#xa0;3B</a>.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" name="table&#xa0;3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;3</b> Pathogenic/likely pathogenic germline <i>BRCA2</i> variants found in our study.</p></div><div class="DottedLine"></div><h3>BRCA1/2 germline VUS</h3><p class="mb0"><i>BRCA1/2</i> variants classified as VUS were found in 7.23% (n=38/525) of the total study population. Regarding <i>BRCA1</i>, eight different VUS were found, with an overall frequency in patients of 1.71% (n = 9/525). Most VUS were reported only in patients with OC (n= 7/8, 87.5%) with a low frequency per variant (n=1/9, 1.1%) and most of them occurred in exon 10. Two VUS had conflicting classifications between ClinVar and the ACMG guidelines: <i>BRCA1</i> c.93C&gt;G (n = 2/9, 2.22%) and <i>BRCA1</i> c.287A&gt;G (<a href="#h10">Table S1</a>). The overall frequency of VUS in <i>BRCA2</i> was 5.52% (n=29/525). We identified 21 different VUS in <i>BRCA2</i> and the most frequent were c.5465A&gt;T (n = 4, 13.79%), followed by c.3101T&gt;C (n = 3, 10.34%), c.205C&gt;A and c.437T&gt;C (n = 2, 6.89%). Similarly, many of the VUS occurred in exon 11 (n = 9/21, 42.86%) and were reported only in patients with OC (n = 14/21, 66.67%). Variants c.2274T&gt;G, c.3509C&gt;T, c.7617 + 6T&gt;C, c.7759C&gt;T, and c.8462T&gt;C had conflicting classifications between the ACMG guidelines and ClinVar (<a href="#h10">Table S1</a>). In addition the pathogenic scores of VUS founds in this study are also presented in <a href="#h10">Table S1</a>.</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">Breast and ovarian cancers are malignancies with a high incidence and prevalence in Latin American women. Costs of treatment and disability adjusted life years directly impact public health systems and society. The management of BC and OC is rapidly evolving with the discovery of new treatments that offer an improved survival advantage, as seen in recent years with PARP inhibitors in <i>BRCA1/2</i> mutation carriers (<a href="#B19">19</a>)</p><p class="mb15">There is limited information on the molecular epidemiology of BRCA1/2 in Peru. Although a third of the Peruvian population lives in Lima, there are economic and geographic barriers that make it difficult for patients to access adequate cancer care, including molecular tests and genetic counseling (<a href="#B20">20</a>). Our work has some limitations, for example, the underrepresentation of patients from several regions of Peru, which have socioeconomic and ancestry differences with respect to Lima. Another limitation that could cause bias is that the study population was selected for possible treatment with PARP inhibitors (e.g., advanced-stage cancer, HER2-negative breast cancer).</p><p class="mb15">The study of <i>BRCA1/2</i> variants in these patients is crucial to identify candidates for these treatments, but is also important to manage their future cancer risks. Patients with <i>BRCA1/2</i> mutations and their families can benefit from cancer risk reduction or early cancer detection strategies, such as double mastectomy or high-risk follow-up for BC and bilateral salpingo-oophorectomy for OC (<a href="#B12">12</a>).</p><p class="mb15">Latin American countries usually have less infrastructure and resources for genetic testing and treatment of patients with <i>BRCA1/2</i> than developed countries, and many of the cancer drugs approved in other countries are not available (<a href="#B21">21</a>). Therefore, genetic testing is not always performed when needed. The interpretation of genetic variants can be more difficult in less-studied populations, and there are no specific open databases for variants in cancer-predisposing genes in Hispanic patients.</p><p class="mb15"><i>BRCA1</i> c.2105dupT was the most frequently found variant in this study. It is located in the coding exon 10 and causes a translational frameshift with a predicted alternate stop codon. This alteration is expected to result in loss of function, according to ClinVar. Until now, this variant was previously reported in 6 of 44 (13.6%) mutated patients with ovarian cancer belonging to the Peruvian population. Furthermore, it was reported only once in the Canadian population. A similar variant, <i>BRCA1</i> c.2105dup, was identified in Caucasian and Hispanic individuals in a study that included only female carriers with pathogenic variants in <i>BRCA1</i>/2 <i>(</i><a href="#B22">22</a>)</p><p class="mb15">In our cohort, we observed the <i>BRCA1</i> c.68_69delAG mutation (185delAG), which occurs in exon 2 and creates a stop codon at position 39. This alteration leads to premature translation termination and significant protein truncation (<a href="#B23">23</a>). Regarding its origin, it constitutes one of the primary founder mutations in the Ashkenazi Jewish population that arose 61 generations ago and was introduced into the Hispanic population 650 years ago (<a href="#B24">24</a>). Currently, it has been reported among several other non-Jewish ethnic groups, such as Peruvians, Mexicans, Colombians, and Brazilians (<a href="#B25">25</a>&#x2013;<a href="#B28">28</a>). A study in Peruvian patients diagnosed with breast cancer showed that 185delAG was the most common mutation found, observed in 7 of 13 carriers (54%). They also noted that two mutation carriers identified as of indigenous ancestry had the <i>BRCA1</i> 185delAG mutation (<a href="#B28">28</a>). Unlike that study, we found that the mutation was observed in people born in Lima and Lambayeque. While it has not been determined whether they share an indigenous or Jewish ancestry, it is known that although the 185delAG mutation resides in a common haplotype among Ashkenazi Jews, it also arose independently in at least two non-Jewish populations, such as those in Malaysia and the United Kingdom. On the other hand, the <i>BRCA1</i> c.140G&gt;T mutation is a missense variant, which occurs within exon 5 and the RING domain. It was previously reported as a VUS in Peruvian families with hereditary breast and ovarian cancer (<a href="#B18">18</a>, <a href="#B24">24</a>). However, it was also identified in the Norwegian population as a pathogenic and non-founder mutation (<a href="#B29">29</a>).</p><p class="mb0">The <i>BRCA1</i> c.815_824dupAGCCATGTGG variant is located in exon 10 and is the most common pathogenic variant reported in African Americans (<a href="#B30">30</a>). This pathogenic variant results in a frameshift and a spurious stop codon of 14 amino acids downstream. Due to its African origin, the variant was found in inherited patients with BC from Senegal and its allele frequency was 27.7%. In that study, the variant was also detected in a control population of sporadic BC cases and healthy controls without cancer (allele frequency estimated at 5% and 0.55%, respectively) (<a href="#B31">31</a>). This variant was also found in Latin American populations, such as Colombian, Peruvian and Mexican (<a href="#B18">18</a>, <a href="#B32">32</a>, <a href="#B33">33</a>). In <a href="#T4">Table&#xa0;4</a>, we summarize and compare our findings with those of other populations. Because we evaluated a very specific group of patients, comparison of prevalence of P/LP variants with other populations it would not be appropriate.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" name="table&#xa0;4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg" alt="www.frontiersin.org" id="T4" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;4</b> Previous reports of <i>BRCA1/2</i> variants found in this study in different populations.</p></div><div class="DottedLine"></div><p class="mb0">In conclusion, in this selected Peruvian population, we found a frequency of 14.7% <i>BRCA1/2</i> germline mutations in BC and 20.7% in OC. The most recurrent mutations were <i>BRCA1</i> c.2105dupT and BRCA2 c.8023A&gt;G. On the other hand, BRCA2 c.8023A&gt;G, c.6024dupG and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database.</p><a id="h6" name="h6"></a><h2>Data availability statement</h2><p class="mb0">The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<a href="#h10">Supplementary Material</a>.</p><a id="h7" name="h7"></a><h2>Ethics statement</h2><p class="mb0">The study was approved by the Institutional Review Board of the Universidad Privada San Juan Bautista (418-2021-CIEI-UPSJB) and conducted in compliance with all relevant ethical guidelines. Due to the retrospective nature of the study, the informed consent was waived.</p><a id="h8" name="h8"></a><h2>Author contributions</h2><p class="mb15">CB-L, JC, and FD conducted molecular assays and collected the data. CB-L, FD, YF, GR, and AC-R conducted analysis of variants. YF, GR, JA, LB, and JP conducted statistical analysis. MC conducted the bioinformatic analysis. YF, GR, JA, LB, and JP prepared <a href="#T1">Tables&#xa0;1</a>, <a href="#T2">2</a>. YF, GR, JA, LB, and JP prepared <a href="#f1">Figures&#xa0;1</a>-<a href="#f3">3</a>. All authors wrote the manuscript. All authors contributed to the article and approved the submitted version.</p><a id="h9" name="h9"></a><h2>Conflict of interest</h2><p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h10" name="h10"></a><h2>Publisher&#x2019;s note</h2><p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p><a id="h11" name="h11"></a><h2>Supplementary material</h2><p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1227864/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2023.1227864/full#supplementary-material</a></p><a id="h13" name="h13"></a><h2>Abbreviations</h2><p class="mb15">VUS, Variants of Uncertain/Unknown Significance; PARP, Poly (Adenosine Diphosphate&#x2013;Ribose) Polymerase; BC, Breast Cancer; OC, Ovarian Cancer; HBOC, Hereditary Breast and Ovarian Cancer; SSB, single-strand break repair, DSBs, Double-Strand DNA Breaks; CT, Chemotherapy; PFS, Progression-free survival; TNBC, Triple Negative Patients; CR/PR, Complete or Partial Response; HRD, Homologous Recombination Deficient; HER2, Human Epidermal Growth Factor Receptor 2; P/PL, Pathogenic/Likely Pathogenic; SNVs, Single Nucleotide Variants; PCR, Polymerase Chain Reaction; HGVS, Human Genome Variation Society (HGVS); dbSNP, Single Nucleotide Polymorphism Database; BIC, Breast Cancer Information Core; ACMG, American College of Medical Genetics.</p><a id="h13" name="h13"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i> (2021) 71(3):209&#x2013;49. doi: 10.3322/caac.21660</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21660" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Sung&amp;author=J+Ferlay&amp;author=RL+Siegel&amp;author=M+Laversanne&amp;author=I+Soerjomataram&amp;author=A+Jemal&amp;publication_year=2021&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA+Cancer+J+Clin&amp;volume=71&amp;pages=209-49" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. <i>Breast Cancer</i> (2021) 28(6):1167&#x2013;80. doi: 10.1007/s12282-020-01148-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32862296/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s12282-020-01148-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Yoshida&amp;publication_year=2021&amp;title=Hereditary%20breast%20and%20ovarian%20cancer%20%28HBOC%29%3A%20review%20of%20its%20molecular%20characteristics%2C%20screening%2C%20treatment%2C%20and%20prognosis&amp;journal=Breast+Cancer&amp;volume=28&amp;pages=1167-80" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Saleem M, Ghazali MB, Wahab MAMA, Yusoff NM, Mahsin H, Seng CE, et al. The BRCA1 and BRCA2 genes in early-onset breast cancer patients. <i>Adv Exp Med Biol</i> (2020) 1292:1&#x2013;12. doi:&#xa0;10.1007/5584_2018_147</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29687286/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/5584_2018_147" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Saleem&amp;author=MB+Ghazali&amp;author=MAMA+Wahab&amp;author=NM+Yusoff&amp;author=H+Mahsin&amp;author=CE+Seng&amp;publication_year=2020&amp;title=The%20BRCA1%20and%20BRCA2%20genes%20in%20early-onset%20breast%20cancer%20patients&amp;journal=Adv+Exp+Med+Biol&amp;volume=1292&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Petrucelli N, Daly MB, Pal T. <i>BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer</i> (2022). GeneReviews&#xae;. Available at: <a href="https://www.ncbi.nlm.nih.gov/books/NBK1247/">https://www.ncbi.nlm.nih.gov/books/NBK1247/</a> (Accessed cited 2023 Jul 11).</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="http://scholar.google.com/scholar_lookup?author=N+Petrucelli&amp;author=MB+Daly&amp;author=T+Pal&amp;publication_year=2022&amp;journal=BRCA1-+and+BRCA2-Associated+Hereditary+Breast+and+Ovarian+Cancer&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. <i>Cancer Res</i> (2006) 66(16):8297&#x2013;308. doi: 10.1158/0008-5472.CAN-06-0503</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16912212/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/0008-5472.CAN-06-0503" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KE+Malone&amp;author=JR+Daling&amp;author=DR+Doody&amp;author=L+Hsu&amp;author=L+Bernstein&amp;author=RJ+Coates&amp;publication_year=2006&amp;title=Prevalence%20and%20predictors%20of%20BRCA1%20and%20BRCA2%20mutations%20in%20a%20population-based%20study%20of%20breast%20cancer%20in%20white%20and%20black%20American%20women%20ages%2035%20to%2064%20years&amp;journal=Cancer+Res&amp;volume=66&amp;pages=8297-308" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D&#x2019;Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. <i>Cancer Discovery</i> (2015) 5(11):1137&#x2013;54. doi: 10.1158/2159-8290.CD-15-0714</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26463832/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/2159-8290.CD-15-0714" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PA+Konstantinopoulos&amp;author=R+Ceccaldi&amp;author=GI+Shapiro&amp;author=AD+D%E2%80%99Andrea&amp;publication_year=2015&amp;title=Homologous%20recombination%20deficiency%3A%20exploiting%20the%20fundamental%20vulnerability%20of%20ovarian%20cancer&amp;journal=Cancer+Discovery&amp;volume=5&amp;pages=1137-54" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiol Biomarkers Prev</i> (2012) 21(1):134&#x2013;47. doi: 10.1158/1055-9965.EPI-11-0775</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22144499/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.EPI-11-0775" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Mavaddat&amp;author=D+Barrowdale&amp;author=IL+Andrulis&amp;author=SM+Domchek&amp;author=D+Eccles&amp;author=H+Nevanlinna&amp;publication_year=2012&amp;title=Pathology%20of%20breast%20and%20ovarian%20cancers%20among%20BRCA1%20and%20BRCA2%20mutation%20carriers%3A%20results%20from%20the%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%2F2%20%28CIMBA%29&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=21&amp;pages=134-47" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. <i>Hum Mol Genet</i> (2014) 23(17):4703&#x2013;9. doi: 10.1093/hmg/ddu172</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24728189/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/ddu172" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=MS+Cicek&amp;author=E+Dicks&amp;author=P+Harrington&amp;author=SJ+Ramus&amp;author=JM+Cunningham&amp;publication_year=2014&amp;title=The%20contribution%20of%20deleterious%20germline%20mutations%20in%20BRCA1%2C%20BRCA2%20and%20the%20mismatch%20repair%20genes%20to%20ovarian%20cancer%20in%20the%20population&amp;journal=Hum+Mol+Genet&amp;volume=23&amp;pages=4703-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Farmer H, McCabe H, Lord CJ, Tutt AHJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. <i>Nature</i> (2005) 434(7035):917&#x2013;21. doi: 10.1038/nature03445</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15829967/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature03445" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Farmer&amp;author=H+McCabe&amp;author=CJ+Lord&amp;author=AHJ+Tutt&amp;author=DA+Johnson&amp;author=TB+Richardson&amp;publication_year=2005&amp;title=Targeting%20the%20DNA%20repair%20defect%20in%20BRCA%20mutant%20cells%20as%20a%20therapeutic%20strategy&amp;journal=Nature&amp;volume=434&amp;pages=917-21" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B10" id="B10"></a> 10. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. <i>N Engl J Med</i> (2017) 377(6):523&#x2013;33. doi: 10.1056/NEJMoa1706450</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1706450" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Robson&amp;author=SA+Im&amp;author=E+Senkus&amp;author=B+Xu&amp;author=SM+Domchek&amp;author=N+Masuda&amp;publication_year=2017&amp;title=Olaparib%20for%20metastatic%20breast%20cancer%20in%20patients%20with%20a%20germline%20BRCA%20mutation&amp;journal=N+Engl+J+Med&amp;volume=377&amp;pages=523-33" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B11" id="B11"></a> 11. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon&#xe7;alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. <i>New Engl J Med</i> (2018) 379(8):753&#x2013;63. doi:&#xa0;10.1056/nejmoa1802905</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30110579/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/nejmoa1802905" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JK+Litton&amp;author=HS+Rugo&amp;author=J+Ettl&amp;author=SA+Hurvitz&amp;author=A+Gon%C3%A7alves&amp;author=KH+Lee&amp;publication_year=2018&amp;title=Talazoparib%20in%20patients%20with%20advanced%20breast%20cancer%20and%20a%20germline%20BRCA%20mutation&amp;journal=New+Engl+J+Med&amp;volume=379&amp;pages=753-63" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B12" id="B12"></a> 12. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. <i>J Natl Compr Canc Netw</i> (2022) 20(6):691&#x2013;722. doi:&#xa0;10.6004/jnccn.2022.0030</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35714673/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.6004/jnccn.2022.0030" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WJ+Gradishar&amp;author=MS+Moran&amp;author=J+Abraham&amp;author=R+Aft&amp;author=D+Agnese&amp;author=KH+Allison&amp;publication_year=2022&amp;title=Breast%20cancer%2C%20version%203.2022%2C%20NCCN%20clinical%20practice%20guidelines%20in%20oncology&amp;journal=J+Natl+Compr+Canc+Netw&amp;volume=20&amp;pages=691" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B13" id="B13"></a> 13. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. <i>N Engl J Med</i> (2018) 379(26):2495&#x2013;505. doi: 10.1056/NEJMoa1810858</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30345884/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1810858" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Moore&amp;author=N+Colombo&amp;author=G+Scambia&amp;author=BG+Kim&amp;author=A+Oaknin&amp;author=M+Friedlander&amp;publication_year=2018&amp;title=Maintenance%20olaparib%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer&amp;journal=N+Engl+J+Med&amp;volume=379&amp;pages=2495-505" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B14" id="B14"></a> 14. Ray-Coquard I, Pautier P, Pignata S, P&#xe9;rol D, Gonz&#xe1;lez-Mart&#xed;n A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. <i>New Engl J Med</i> (2019) 381(25):2416&#x2013;28. doi:&#xa0;10.1056/nejmoa1911361</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31851799/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/nejmoa1911361" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Ray-Coquard&amp;author=P+Pautier&amp;author=S+Pignata&amp;author=D+P%C3%A9rol&amp;author=A+Gonz%C3%A1lez-Mart%C3%ADn&amp;author=R+Berger&amp;publication_year=2019&amp;title=Olaparib%20plus%20bevacizumab%20as%20first-line%20maintenance%20in%20ovarian%20cancer&amp;journal=New+Engl+J+Med&amp;volume=381&amp;pages=2416-28" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B15" id="B15"></a> 15. Gonz&#xe1;lez-Mart&#xed;n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. <i>New Engl J Med</i> (2019) 381(25):2391&#x2013;402. doi:&#xa0;10.1056/NEJMoa1910962</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31562799/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1910962" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Gonz%C3%A1lez-Mart%C3%ADn&amp;author=B+Pothuri&amp;author=I+Vergote&amp;author=R+DePont%20Christensen&amp;author=W+Graybill&amp;author=MR+Mirza&amp;publication_year=2019&amp;title=Niraparib%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer&amp;journal=New+Engl+J+Med&amp;volume=381&amp;pages=2391-402" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B16" id="B16"></a> 16. Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic epidemiology of breast cancer in Latin America. <i>Genes (Basel)</i> (2019) 10(2). doi: 10.3390/genes10020153</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30781715/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/genes10020153" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=VA+Zavala&amp;author=SJ+Serrano-Gomez&amp;author=J+Dutil&amp;author=L+Fejerman&amp;publication_year=2019&amp;title=Genetic%20epidemiology%20of%20breast%20cancer%20in%20Latin%20America&amp;journal=Genes+(Basel)&amp;volume=10&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B17" id="B17"></a> 17. Ossa CA, Torres D. Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries: state of the art and literature review. <i>Oncologist</i> (2016) 21(7):832&#x2013;9. doi: 10.1634/theoncologist.2015-0416</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27286788/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1634/theoncologist.2015-0416" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CA+Ossa&amp;author=D+Torres&amp;publication_year=2016&amp;title=Founder%20and%20recurrent%20mutations%20in%20BRCA1%20and%20BRCA2%20genes%20in%20Latin%20American%20countries%3A%20state%20of%20the%20art%20and%20literature%20review&amp;journal=Oncologist&amp;volume=21&amp;pages=832-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B18" id="B18"></a> 18. Buleje J, Guevara-Fujita M, Acosta O, Huaman FDP, Danos P, Murillo A, et al. Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. <i>Mol Genet Genomic Med</i> (2017) 5(5). doi: 10.1002/mgg3.301</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28944232/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/mgg3.301" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Buleje&amp;author=M+Guevara-Fujita&amp;author=O+Acosta&amp;author=FDP+Huaman&amp;author=P+Danos&amp;author=A+Murillo&amp;publication_year=2017&amp;title=Mutational%20analysis%20of%20BRCA1%20and%20BRCA2%20genes%20in%20Peruvian%20families%20with%20hereditary%20breast%20and%20ovarian%20cancer&amp;journal=Mol+Genet+Genomic+Med&amp;volume=5&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B19" id="B19"></a> 19. Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, et al. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. <i>Aging</i> (2021) 13(6):8975&#x2013;88. doi: 10.18632/aging.202724</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33705352/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/aging.202724" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Shao&amp;author=Y+Duan&amp;author=Y+Zhao&amp;author=Y+Li&amp;author=J+Liu&amp;author=C+Zhang&amp;publication_year=2021&amp;title=PARP%20inhibitors%20in%20breast%20and%20ovarian%20cancer%20with%20BRCA%20mutations%3A%20a%20meta-analysis%20of%20survival&amp;journal=Aging&amp;volume=13&amp;pages=8975-88" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B20" id="B20"></a> 20. Pinto JA, Pinillos L, Villarreal-Garza C, Morante Z, Villar&#xe1;n MV, Mej&#xed;a G, et al. Barriers in Latin America for the management of locally advanced breast cancer. <i>Ecancermedicalscience</i> (2019) 13. doi: 10.3332/ecancer.2019.897</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3332/ecancer.2019.897" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JA+Pinto&amp;author=L+Pinillos&amp;author=C+Villarreal-Garza&amp;author=Z+Morante&amp;author=MV+Villar%C3%A1n&amp;author=G+Mej%C3%ADa&amp;publication_year=2019&amp;title=Barriers%20in%20Latin%20America%20for%20the%20management%20of%20locally%20advanced%20breast%20cancer&amp;journal=Ecancermedicalscience&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B21" id="B21"></a> 21. Horgan D, Mia R, Erhabor T, Hamdi Y, Dandara C, Lal JA, et al. Fighting cancer around the world: A framework for action. <i>Healthc (Basel)</i> (2022) 10(11). doi: 10.3390/healthcare10112125</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/healthcare10112125" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Horgan&amp;author=R+Mia&amp;author=T+Erhabor&amp;author=Y+Hamdi&amp;author=C+Dandara&amp;author=JA+Lal&amp;publication_year=2022&amp;title=Fighting%20cancer%20around%20the%20world%3A%20A%20framework%20for%20action&amp;journal=Healthc+(Basel)&amp;volume=10&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B22" id="B22"></a> 22. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Hum Mutat</i> (2018) 39(5):593&#x2013;620. doi: 10.1002/humu.23406</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29446198/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23406" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=TM+Friebel&amp;author=E+Friedman&amp;author=U+Hamann&amp;author=D+Huo&amp;author=A+Kwong&amp;publication_year=2018&amp;title=Mutational%20spectrum%20in%20a%20worldwide%20study%20of%2029%2C700%20families%20with%20BRCA1%20or%20BRCA2%20mutations&amp;journal=Hum+Mutat&amp;volume=39&amp;pages=593" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B23" id="B23"></a> 23. Hartwig M, Janiszewska H, Bak A, Pilarska M, Heise M, Junkiert-Czarnecka A, et al. Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country. <i>Contemp Oncol (Pozn)</i> (2013) 17(1):34&#x2013;7. doi:&#xa0;10.5114/wo.2013.33767</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23788959/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.5114/wo.2013.33767" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Hartwig&amp;author=H+Janiszewska&amp;author=A+Bak&amp;author=M+Pilarska&amp;author=M+Heise&amp;author=A+Junkiert-Czarnecka&amp;publication_year=2013&amp;title=Prevalence%20of%20the%20BRCA1%20c.68_69delAG%20%28BIC%3A%20185delAG%29%20mutation%20in%20women%20with%20breast%20cancer%20from%20north-central%20Poland%20and%20a%20review%20of%20the%20literature%20on%20other%20regions%20of%20the%20country&amp;journal=Contemp+Oncol+(Pozn)&amp;volume=17&amp;pages=34-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B24" id="B24"></a> 24. Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, et al. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. <i>Eur J Hum Genet</i> (2013) 21(2):212&#x2013;6. doi: 10.1038/ejhg.2012.124</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22763381/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ejhg.2012.124" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Laitman&amp;author=BJ+Feng&amp;author=IM+Zamir&amp;author=JN+Weitzel&amp;author=P+Duncan&amp;author=D+Port&amp;publication_year=2013&amp;title=Haplotype%20analysis%20of%20the%20185delAG%20BRCA1%20mutation%20in%20ethnically%20diverse%20populations&amp;journal=Eur+J+Hum+Genet&amp;volume=21&amp;pages=212-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B25" id="B25"></a> 25. Villarreal-Garza C, Alvarez-G&#xf3;mez RM, P&#xe9;rez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. <i>Cancer</i> (2015) 121(3):372&#x2013;8. doi: 10.1002/cncr.29058</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25236687/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.29058" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Villarreal-Garza&amp;author=RM+Alvarez-G%C3%B3mez&amp;author=C+P%C3%A9rez-Plasencia&amp;author=LA+Herrera&amp;author=J+Herzog&amp;author=D+Castillo&amp;publication_year=2015&amp;title=Significant%20clinical%20impact%20of%20recurrent%20BRCA1%20and%20BRCA2%20mutations%20in%20Mexico&amp;journal=Cancer&amp;volume=121&amp;pages=372-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B26" id="B26"></a> 26. Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. <i>Fam Cancer</i> (2018) 17(1):23&#x2013;30. doi: 10.1007/s10689-017-0004-z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28528518/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10689-017-0004-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AM+Cock-Rada&amp;author=CA+Ossa&amp;author=HI+Garcia&amp;author=LR+Gomez&amp;publication_year=2018&amp;title=A%20multi-gene%20panel%20study%20in%20hereditary%20breast%20and%20ovarian%20cancer%20in%20Colombia&amp;journal=Fam+Cancer&amp;volume=17&amp;pages=23" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B27" id="B27"></a> 27. Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, et al. Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. <i>Genet Mol Biol</i> (2012) 35(3):599&#x2013;602. doi: 10.1590/S1415-47572012000400009</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23055798/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1590/S1415-47572012000400009" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CV+Dillenburg&amp;author=IC+Bandeira&amp;author=TV+Tubino&amp;author=LG+Rossato&amp;author=ES+Dias&amp;author=AC+Bittelbrunn&amp;publication_year=2012&amp;title=Prevalence%20of%20185delAG%20and%205382insC%20mutations%20in%20BRCA1%2C%20and%206174delT%20in%20BRCA2%20in%20women%20of%20Ashkenazi%20Jewish%20origin%20in%20southern%20Brazil&amp;journal=Genet+Mol+Biol&amp;volume=35&amp;pages=599" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B28" id="B28"></a> 28. Abugattas J, Llacuachaqui M, Allende YS, Vel&#xe1;squez AA, Velarde R, Cotrina J, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. <i>Clin Genet</i> (2015) 88(4):371&#x2013;5. doi: 10.1111/cge.12505</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25256238/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12505" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Abugattas&amp;author=M+Llacuachaqui&amp;author=YS+Allende&amp;author=AA+Vel%C3%A1squez&amp;author=R+Velarde&amp;author=J+Cotrina&amp;publication_year=2015&amp;title=Prevalence%20of%20BRCA1%20and%20BRCA2%20mutations%20in%20unselected%20breast%20cancer%20patients%20from%20Peru&amp;journal=Clin+Genet&amp;volume=88&amp;pages=371-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B29" id="B29"></a> 29. Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. <i>Hered Cancer Clin Pract</i> (2018) 16(1):1&#x2013;15. doi:&#xa0;10.1186/s13053-017-0085-6</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29308099/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13053-017-0085-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Heramb&amp;author=T+Wangensteen&amp;author=EM+Grindedal&amp;author=SL+Ariansen&amp;author=S+Lothe&amp;author=KR+Heimdal&amp;publication_year=2018&amp;title=BRCA1%20and%20BRCA2%20mutation%20spectrum%20-%20an%20update%20on%20mutation%20distribution%20in%20a%20large%20cancer%20genetics%20clinic%20in%20Norway&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=16&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B30" id="B30"></a> 30. Scheuner MT, McNeel TS, Freedman AN. Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey. <i>Genet Med</i> (2010) 12(11):726&#x2013;35. doi:&#xa0;10.1097/GIM.0b013e3181f30e9e</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20921897/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/GIM.0b013e3181f30e9e" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MT+Scheuner&amp;author=TS+McNeel&amp;author=AN+Freedman&amp;publication_year=2010&amp;title=Population%20prevalence%20of%20familial%20cancer%20and%20common%20hereditary%20cancer%20syndromes.%20The%202005%20California%20Health%20Interview%20Survey&amp;journal=Genet+Med&amp;volume=12&amp;pages=726-35" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B31" id="B31"></a> 31. Ndiaye R, Diop JPD, Bourdon-Huguenin V, Dem A, Diouf D, Dieng MM, et al. Evidence for an ancient BRCA 1 pathogenic variant in inherited breast cancer patients from Senegal. <i>NPJ Genom Med</i> (2020) 5(1). doi: 10.1038/s41525-020-0114-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32025337/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41525-020-0114-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Ndiaye&amp;author=JPD+Diop&amp;author=V+Bourdon-Huguenin&amp;author=A+Dem&amp;author=D+Diouf&amp;author=MM+Dieng&amp;publication_year=2020&amp;title=Evidence%20for%20an%20ancient%20BRCA%201%20pathogenic%20variant%20in%20inherited%20breast%20cancer%20patients%20from%20Senegal&amp;journal=NPJ+Genom+Med&amp;volume=5&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B32" id="B32"></a> 32. Vargas E, Torres Lopez DM, Deugd R, Gil F, Nova A, Mora L, et al. Low prevalence of the four common Colombian founder mutations in BRCA1 and BRCA2 in early-onset and familial afro-Colombian patients with breast cancer. <i>Oncologist</i> (2019) 24(7):e475&#x2013;9. doi: 10.1634/theoncologist.2018-0346</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30541753/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1634/theoncologist.2018-0346" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Vargas&amp;author=DM+Torres%20Lopez&amp;author=R+Deugd&amp;author=F+Gil&amp;author=A+Nova&amp;author=L+Mora&amp;publication_year=2019&amp;title=Low%20prevalence%20of%20the%20four%20common%20Colombian%20founder%20mutations%20in%20BRCA1%20and%20BRCA2%20in%20early-onset%20and%20familial%20afro-Colombian%20patients%20with%20breast%20cancer&amp;journal=Oncologist&amp;volume=24&amp;pages=e475-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B33" id="B33"></a> 33. Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, et al. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. <i>NPJ Breast Cancer</i> (2021) 7(1). doi: 10.1038/s41523-021-00317-6</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34413315/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41523-021-00317-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JS+Herzog&amp;author=Y+Chavarri-Guerra&amp;author=D+Castillo&amp;author=J+Abugattas&amp;author=C+Villarreal-Garza&amp;author=S+Sand&amp;publication_year=2021&amp;title=Genetic%20epidemiology%20of%20BRCA1-%20and%20BRCA2-associated%20cancer%20across%20Latin%20America&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B34" id="B34"></a> 34. Molina J, Fernandez OOC, Lim M, Mas L, Veliz IF, Vargas C. BRCA 1/2 mutations in high-grade serous ovarian cancer (HGS-OC) patients of three Latin American countries: Report of 412 cases. <i>J Clin Oncol</i> (2019) 37(15_suppl):e14288&#x2013;8. doi: 10.1200/JCO.2019.37.15_suppl.e14288</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1200/JCO.2019.37.15_suppl.e14288" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Molina&amp;author=OOC+Fernandez&amp;author=M+Lim&amp;author=L+Mas&amp;author=IF+Veliz&amp;author=C+Vargas&amp;publication_year=2019&amp;title=BRCA%201%2F2%20mutations%20in%20high-grade%20serous%20ovarian%20cancer%20%28HGS-OC%29%20patients%20of%20three%20Latin%20American%20countries%3A%20Report%20of%20412%20cases&amp;journal=J+Clin+Oncol&amp;volume=37&amp;pages=e14288-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B35" id="B35"></a> 35. Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. <i>Biol Res</i> (2017) 50(1). doi: 10.1186/s40659-017-0139-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28985766/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s40659-017-0139-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Jara&amp;author=S+Morales&amp;author=T+de%20Mayo&amp;author=P+Gonzalez-Hormazabal&amp;author=V+Carrasco&amp;author=R+Godoy&amp;publication_year=2017&amp;title=Mutations%20in%20BRCA1%2C%20BRCA2%20and%20other%20breast%20and%20ovarian%20cancer%20susceptibility%20genes%20in%20Central%20and%20South%20American%20populations&amp;journal=Biol+Res&amp;volume=50&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B36" id="B36"></a> 36. Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Guti&#xe9;rrez LG. Study of the genetic variants in BRCA1/2 and non- BRCA genes in a population-based cohort of 2155 breast/ovary cancer patients, including 443 triple-negative breast cancer patients, in Argentina. <i>Cancers (Basel)</i> (2021) 13(11). doi: 10.3390/cancers13112711</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34072659/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/cancers13112711" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AR+Solano&amp;author=PG+Mele&amp;author=FS+Jalil&amp;author=NC+Liria&amp;author=EJ+Podesta&amp;author=LG+Guti%C3%A9rrez&amp;publication_year=2021&amp;title=Study%20of%20the%20genetic%20variants%20in%20BRCA1%2F2%20and%20non-%20BRCA%20genes%20in%20a%20population-based%20cohort%20of%202155%20breast%2Fovary%20cancer%20patients%2C%20including%20443%20triple-negative%20breast%20cancer%20patients%2C%20in%20Argentina&amp;journal=Cancers+(Basel)&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B37" id="B37"></a> 37. Bhaskaran SP, Huang T, Rajendran BK, Guo M, Luo J, Qin Z, et al. Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations. <i>J Med Genet</i> (2021) 58(11):752&#x2013;9. doi: 10.1136/jmedgenet-2020-107299</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32963034/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmedgenet-2020-107299" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SP+Bhaskaran&amp;author=T+Huang&amp;author=BK+Rajendran&amp;author=M+Guo&amp;author=J+Luo&amp;author=Z+Qin&amp;publication_year=2021&amp;title=Ethnic-specific%20BRCA1%2F2%20variation%20within%20Asia%20population%3A%20evidence%20from%20over%2078%20000%20cancer%20and%2040%20000%20non-cancer%20cases%20of%20Indian%2C%20Chinese%2C%20Korean%20and%20Japanese%20populations&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=752-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B38" id="B38"></a> 38. Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubi&#x144;ski J, et al. Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. <i>Hered Cancer Clin Pract</i> (2018) 16(1). doi: 10.1186/s13053-018-0089-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29492181/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13053-018-0089-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Kluz&amp;author=A+Jasiewicz&amp;author=E+Marczyk&amp;author=R+Jach&amp;author=A+Jakubowska&amp;author=J+Lubi%C5%84ski&amp;publication_year=2018&amp;title=Frequency%20of%20BRCA1%20and%20BRCA2%20causative%20founder%20variants%20in%20ovarian%20cancer%20patients%20in%20South-East%20Poland&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=16&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B39" id="B39"></a> 39. Kechin A, Boyarskikh U, Barinov A, Tanas A, Kazakova S, Zhevlova A, et al. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. <i>Breast Cancer Res Treat</i> (2023) 197(2):387&#x2013;95. doi: 10.1007/s10549-022-06782-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/36367610/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-022-06782-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Kechin&amp;author=U+Boyarskikh&amp;author=A+Barinov&amp;author=A+Tanas&amp;author=S+Kazakova&amp;author=A+Zhevlova&amp;publication_year=2023&amp;title=A%20spectrum%20of%20BRCA1%20and%20BRCA2%20germline%20deleterious%20variants%20in%20ovarian%20cancer%20in%20Russia&amp;journal=Breast+Cancer+Res+Treat&amp;volume=197&amp;pages=387-95" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B40" id="B40"></a> 40. Gabald&#xf3; Barrios X, Sarabia Meseguer MD, Mar&#xed;n Vera M, S&#xe1;nchez Berm&#xfa;dez AI, Mac&#xed;as Cerrolaza JA, S&#xe1;nchez Henarejos P, et al. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. <i>Fam Cancer</i> (2017) 16(4):477&#x2013;89. doi: 10.1007/s10689-017-9985-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28477318/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10689-017-9985-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Gabald%C3%B3%20Barrios&amp;author=MD+Sarabia%20Meseguer&amp;author=M+Mar%C3%ADn%20Vera&amp;author=AI+S%C3%A1nchez%20Berm%C3%BAdez&amp;author=JA+Mac%C3%ADas%20Cerrolaza&amp;author=P+S%C3%A1nchez%20Henarejos&amp;publication_year=2017&amp;title=Molecular%20characterization%20and%20clinical%20interpretation%20of%20BRCA1%2FBRCA2%20variants%20in%20families%20from%20Murcia%20%28south-eastern%20Spain%29%20with%20hereditary%20breast%20and%20ovarian%20cancer%3A%20clinical-pathological%20features%20in%20BRCA%20carriers%20and%20non-carriers&amp;journal=Fam+Cancer&amp;volume=16&amp;pages=477-89" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B41" id="B41"></a> 41. Nguyen-Dumont T, Karpinski P, Sasiadek MM, Akopyan H, Steen JA, Theys D, et al. Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer? <i>Genet Res (Camb)</i> (2020) 102. doi: 10.1017/S0016672320000075</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32772980/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1017/S0016672320000075" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Nguyen-Dumont&amp;author=P+Karpinski&amp;author=MM+Sasiadek&amp;author=H+Akopyan&amp;author=JA+Steen&amp;author=D+Theys&amp;publication_year=2020&amp;title=Genetic%20testing%20in%20Poland%20and%20Ukraine%3A%20should%20comprehensive%20germline%20testing%20of%20BRCA1%20and%20BRCA2%20be%20recommended%20for%20women%20with%20breast%20and%20ovarian%20cancer&amp;journal=Genet+Res+(Camb)&amp;volume=102&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B42" id="B42"></a> 42. Manzanares Campillo M, Mu&#xf1;oz Atienza V, S&#xe1;nchez Tapia EM, Mart&#xed;n Fern&#xe1;ndez J. Portadoras de mutaciones en BRCA1 y 2 en familias de alto riesgo del &#xe1;rea de Ciudad Real (Espa&#xf1;a): prevalencia mutacional y caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas del c&#xe1;ncer de mama y ovario. <i>Rev Senol Y Patol Mamaria  J Breast Sci</i> (2018) 31(2):59&#x2013;66. doi:&#xa0;10.1016/j.senol.2018.04.002</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/j.senol.2018.04.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Manzanares%20Campillo&amp;author=V+Mu%C3%B1oz%20Atienza&amp;author=EM+S%C3%A1nchez%20Tapia&amp;author=J+Mart%C3%ADn%20Fern%C3%A1ndez&amp;publication_year=2018&amp;title=Portadoras%20de%20mutaciones%20en%20BRCA1%20y%202%20en%20familias%20de%20alto%20riesgo%20del%20%C3%A1rea%20de%20Ciudad%20Real%20%28Espa%C3%B1a%29%3A%20prevalencia%20mutacional%20y%20caracter%C3%ADsticas%20cl%C3%ADnico-patol%C3%B3gicas%20del%20c%C3%A1ncer%20de%20mama%20y%20ovario&amp;journal=Rev+Senol+Y+Patol+Mamaria++J+Breast+Sci&amp;volume=31&amp;pages=59" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B43" id="B43"></a> 43. Kang PCE, Phuah SY, Sivanandan K, Kang IN, Thirthagiri E, Liu JJ, et al. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history. <i>Breast Cancer Res Treat</i> (2014) 144(3):635&#x2013;42. doi: 10.1007/s10549-014-2894-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24578176/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-014-2894-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PCE+Kang&amp;author=SY+Phuah&amp;author=K+Sivanandan&amp;author=IN+Kang&amp;author=E+Thirthagiri&amp;author=JJ+Liu&amp;publication_year=2014&amp;title=Recurrent%20mutation%20testing%20of%20BRCA1%20and%20BRCA2%20in%20Asian%20breast%20cancer%20patients%20identify%20carriers%20in%20those%20with%20presumed%20low%20risk%20by%20family%20history&amp;journal=Breast+Cancer+Res+Treat&amp;volume=144&amp;pages=635-42" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B44" id="B44"></a> 44. Gallardo-Rinc&#xf3;n D, Montes-Serv&#xed;n E, Alamilla-Garc&#xed;a G, Montes-Serv&#xed;n E, Bahena-Gonz&#xe1;lez A, Cetina-P&#xe9;rez L, et al. Clinical benefits of olaparib in mexican ovarian cancer patients with founder mutation BRCA1-del ex9-12. <i>Front Genet</i> (2022) 13. doi:&#xa0;10.3389/fgene.2022.863956</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35734436/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2022.863956" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Gallardo-Rinc%C3%B3n&amp;author=E+Montes-Serv%C3%ADn&amp;author=G+Alamilla-Garc%C3%ADa&amp;author=E+Montes-Serv%C3%ADn&amp;author=A+Bahena-Gonz%C3%A1lez&amp;author=L+Cetina-P%C3%A9rez&amp;publication_year=2022&amp;title=Clinical%20benefits%20of%20olaparib%20in%20mexican%20ovarian%20cancer%20patients%20with%20founder%20mutation%20BRCA1-del%20ex9-12&amp;journal=Front+Genet&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B45" id="B45"></a> 45. Fernandes GC, Michelli RAD, Galv&#xe3;o HCR, Paula AE, Pereira R, Andrade CE, et al. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. <i>Oncotarget</i> (2016) 7(49):80465&#x2013;81. doi: 10.18632/oncotarget.12610</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27741520/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/oncotarget.12610" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=GC+Fernandes&amp;author=RAD+Michelli&amp;author=HCR+Galv%C3%A3o&amp;author=AE+Paula&amp;author=R+Pereira&amp;author=CE+Andrade&amp;publication_year=2016&amp;title=Prevalence%20of%20BRCA1%2FBRCA2%20mutations%20in%20a%20Brazilian%20population%20sample%20at-risk%20for%20hereditary%20breast%20cancer%20and%20characterization%20of%20its%20genetic%20ancestry&amp;journal=Oncotarget&amp;volume=7&amp;pages=80465-81" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B46" id="B46"></a> 46. Jarhelle E, Riise Stensland HMF, M&#xe6;hle L, Van Ghelue M. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort. <i>Fam Cancer</i> (2017) 16(1):1&#x2013;16. doi: 10.1007/s10689-016-9916-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27495310/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10689-016-9916-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Jarhelle&amp;author=HMF+Riise%20Stensland&amp;author=L+M%C3%A6hle&amp;author=M+Van%20Ghelue&amp;publication_year=2017&amp;title=Characterization%20of%20BRCA1%20and%20BRCA2%20variants%20found%20in%20a%20Norwegian%20breast%20or%20ovarian%20cancer%20cohort&amp;journal=Fam+Cancer&amp;volume=16&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B47" id="B47"></a> 47. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadal&#xf3; L, et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Hum Mutat</i> (2019) 40(9):1557&#x2013;78. doi:&#xa0;10.1002/humu.23818</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31131967/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23818" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MT+Parsons&amp;author=E+Tudini&amp;author=H+Li&amp;author=E+Hahnen&amp;author=B+Wappenschmidt&amp;author=L+Feliubadal%C3%B3&amp;publication_year=2019&amp;title=Large%20scale%20multifactorial%20likelihood%20quantitative%20analysis%20of%20BRCA1%20and%20BRCA2%20variants%3A%20An%20ENIGMA%20resource%20to%20support%20clinical%20variant%20classification&amp;journal=Hum+Mutat&amp;volume=40&amp;pages=1557-78" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B48" id="B48"></a> 48. Ponce J, Vigil C, Araujo J, Casta&#xf1;eda C, Calderon G, Buleje J, et al. Abstract P5-09-08: Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1. <i>Cancer Res</i> (2017) 77(4_Supplement):P5-09-08. doi:&#xa0;10.1158/1538-7445.SABCS16-P5-09-08</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1158/1538-7445.SABCS16-P5-09-08" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Ponce&amp;author=C+Vigil&amp;author=J+Araujo&amp;author=C+Casta%C3%B1eda&amp;author=G+Calderon&amp;author=J+Buleje&amp;publication_year=2017&amp;title=Abstract%20P5-09-08%3A%20Molecular%20evaluation%20of%20Peruvian%20patients%20with%20hereditary%20breast%20cancer%20reveals%20a%20novel%20germline%20mutation%20in%20BRCA1&amp;journal=Cancer+Res&amp;volume=77&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B49" id="B49"></a> 49. Pal T, Bonner D, Cragun D, Monteiro ANA, Phelan C, Servais L, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. <i>Cancer</i> (2015) 121(23):4173&#x2013;80. doi: 10.1002/cncr.29645</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26287763/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.29645" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Pal&amp;author=D+Bonner&amp;author=D+Cragun&amp;author=ANA+Monteiro&amp;author=C+Phelan&amp;author=L+Servais&amp;publication_year=2015&amp;title=A%20high%20frequency%20of%20BRCA%20mutations%20in%20young%20black%20women%20with%20breast%20cancer%20residing%20in%20Florida&amp;journal=Cancer&amp;volume=121&amp;pages=4173-80" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B50" id="B50"></a> 50. D&#xed;ez O, Osorio A, Dur&#xe1;n M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. <i>Hum Mutat</i> (2003) 22(4):301&#x2013;12. doi: 10.1002/humu.10260</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/12955716/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.10260" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O+D%C3%ADez&amp;author=A+Osorio&amp;author=M+Dur%C3%A1n&amp;author=JI+Martinez-Ferrandis&amp;author=M+de%20la%20Hoya&amp;author=R+Salazar&amp;publication_year=2003&amp;title=Analysis%20of%20BRCA1%20and%20BRCA2%20genes%20in%20Spanish%20breast%2Fovarian%20cancer%20patients%3A%20a%20high%20proportion%20of%20mutations%20unique%20to%20Spain%20and%20evidence%20of%20founder%20effects&amp;journal=Hum+Mutat&amp;volume=22&amp;pages=301-12" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B51" id="B51"></a> 51. Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, et al. Non-founder BRCA1 mutations in Russian breast cancer patients. <i>Cancer Lett</i> (2010) 298(2):258&#x2013;63. doi: 10.1016/j.canlet.2010.07.013</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20727672/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.canlet.2010.07.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AG+Iyevleva&amp;author=EN+Suspitsin&amp;author=K+Kroeze&amp;author=TV+Gorodnova&amp;author=AP+Sokolenko&amp;author=KG+Buslov&amp;publication_year=2010&amp;title=Non-founder%20BRCA1%20mutations%20in%20Russian%20breast%20cancer%20patients&amp;journal=Cancer+Lett&amp;volume=298&amp;pages=258-63" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B52" id="B52"></a> 52. Vidal AF, Ferraz RS, El-Husny A, Silva CS, Vinasco-Sandoval T, Magalh&#xe3;es L, et al. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation. <i>BMC Cancer</i> (2021) 21(1). doi: 10.1186/s12885-021-08089-9</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33827469/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12885-021-08089-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AF+Vidal&amp;author=RS+Ferraz&amp;author=A+El-Husny&amp;author=CS+Silva&amp;author=T+Vinasco-Sandoval&amp;author=L+Magalh%C3%A3es&amp;publication_year=2021&amp;title=Comprehensive%20analysis%20of%20germline%20mutations%20in%20northern%20Brazil%3A%20a%20panel%20of%2016%20genes%20for%20hereditary%20cancer-predisposing%20syndrome%20investigation&amp;journal=BMC+Cancer&amp;volume=21&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B53" id="B53"></a> 53. Rogo&#x17c;a-Janiszewska E, Mali&#x144;ska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, et al. Prevalence of recurrent mutations predisposing to breast cancer in early-onset breast cancer patients from Poland. <i>Cancers (Basel)</i> (2020) 12(8):1&#x2013;10. doi:&#xa0;10.3390/cancers12082321</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/cancers12082321" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Rogo%C5%BCa-Janiszewska&amp;author=K+Mali%C5%84ska&amp;author=C+Cybulski&amp;author=A+Jakubowska&amp;author=J+Gronwald&amp;author=T+Huzarski&amp;publication_year=2020&amp;title=Prevalence%20of%20recurrent%20mutations%20predisposing%20to%20breast%20cancer%20in%20early-onset%20breast%20cancer%20patients%20from%20Poland&amp;journal=Cancers+(Basel)&amp;volume=12&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B54" id="B54"></a> 54. Szwiec M, Jakubowska A, G&#xf3;rski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. <i>Clin Genet</i> (2015) 87(3):288&#x2013;92. doi: 10.1111/cge.12360</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24528374/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12360" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Szwiec&amp;author=A+Jakubowska&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=J+Tomiczek-Szwiec&amp;author=J+Gronwald&amp;publication_year=2015&amp;title=Recurrent%20mutations%20of%20BRCA1%20and%20BRCA2%20in%20Poland%3A%20an%20update&amp;journal=Clin+Genet&amp;volume=87&amp;pages=288-92" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B55" id="B55"></a> 55. Blay P, Santamar&#xed;a I, Pitiot AS, Luque M, Alvarado MG, Lastra A, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). <i>BMC Cancer</i> (2013) 13. doi: 10.1186/1471-2407-13-243</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23683081/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1471-2407-13-243" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Blay&amp;author=I+Santamar%C3%ADa&amp;author=AS+Pitiot&amp;author=M+Luque&amp;author=MG+Alvarado&amp;author=A+Lastra&amp;publication_year=2013&amp;title=Mutational%20analysis%20of%20BRCA1%20and%20BRCA2%20in%20hereditary%20breast%20and%20ovarian%20cancer%20families%20from%20Asturias%20%28Northern%20Spain%29&amp;journal=BMC+Cancer&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B56" id="B56"></a> 56. Kim JH, Park S, Park HS, Park JS, Lee ST, Kim SW, et al. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study. <i>Sci Rep</i> (2021) 11(1). doi: 10.1038/s41598-021-87792-w</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41598-021-87792-w" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JH+Kim&amp;author=S+Park&amp;author=HS+Park&amp;author=JS+Park&amp;author=ST+Lee&amp;author=SW+Kim&amp;publication_year=2021&amp;title=Analysis%20of%20BRCA1%2F2%20variants%20of%20unknown%20significance%20in%20the%20prospective%20Korean%20Hereditary%20Breast%20Cancer%20study&amp;journal=Sci+Rep&amp;volume=11&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B57" id="B57"></a> 57. Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, et al. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer</i> (2016) 122(1):84&#x2013;90. doi: 10.1002/cncr.29707</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26439132/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.29707" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Sakamoto&amp;author=Y+Hirotsu&amp;author=H+Nakagomi&amp;author=H+Ouchi&amp;author=A+Ikegami&amp;author=K+Teramoto&amp;publication_year=2016&amp;title=BRCA1%20and%20BRCA2%20mutations%20in%20Japanese%20patients%20with%20ovarian%2C%20fallopian%20tube%2C%20and%20primary%20peritoneal%20cancer&amp;journal=Cancer&amp;volume=122&amp;pages=84" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B58" id="B58"></a> 58. Yamaguchi-Kabata Y, Yasuda J, Tanabe O, Suzuki Y, Kawame H, Fuse N, et al. Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. <i>J Hum Genet</i> (2017) 63(2):213&#x2013;30. doi:&#xa0;10.1038/s10038-017-0347-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29192238/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s10038-017-0347-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Yamaguchi-Kabata&amp;author=J+Yasuda&amp;author=O+Tanabe&amp;author=Y+Suzuki&amp;author=H+Kawame&amp;author=N+Fuse&amp;publication_year=2017&amp;title=Evaluation%20of%20reported%20pathogenic%20variants%20and%20their%20frequencies%20in%20a%20Japanese%20population%20based%20on%20a%20whole-genome%20reference%20panel%20of%202049%20individuals&amp;journal=J+Hum+Genet&amp;volume=63&amp;pages=213-30" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B59" id="B59"></a> 59. Tokunaga H, Iida K, Hozawa A, Ogishima S, Watanabe Y, Shigeta S, et al. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). <i>PloS One</i> (2021) 16(1). doi: 10.1371/journal.pone.0236907</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1371/journal.pone.0236907" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Tokunaga&amp;author=K+Iida&amp;author=A+Hozawa&amp;author=S+Ogishima&amp;author=Y+Watanabe&amp;author=S+Shigeta&amp;publication_year=2021&amp;title=Novel%20candidates%20of%20pathogenic%20variants%20of%20the%20BRCA1%20and%20BRCA2%20genes%20from%20a%20dataset%20of%203%2C552%20Japanese%20whole%20genomes%20%283.5KJPNv2%29&amp;journal=PloS+One&amp;volume=16&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B60" id="B60"></a> 60. Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. <i>Mol Genet Genomic Med</i> (2015) 3(2):121&#x2013;9. doi: 10.1002/mgg3.120</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25802882/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/mgg3.120" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Hirotsu&amp;author=H+Nakagomi&amp;author=I+Sakamoto&amp;author=K+Amemiya&amp;author=H+Mochizuki&amp;author=M+Omata&amp;publication_year=2015&amp;title=Detection%20of%20BRCA1%20and%20BRCA2%20germline%20mutations%20in%20Japanese%20population%20using%20next-generation%20sequencing&amp;journal=Mol+Genet+Genomic+Med&amp;volume=3&amp;pages=121-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B61" id="B61"></a> 61. Torres-Mej&#xed;a G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Mart&#xed;nez-Matsushita L, et al. Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. <i>Cancer Epidemiol Biomarkers Prev</i> (2015) 24(3):498&#x2013;505. doi: 10.1158/1055-9965.EPI-13-0980</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25371446/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.EPI-13-0980" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Torres-Mej%C3%ADa&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=MR+Akbari&amp;author=AR+Giuliano&amp;author=L+Mart%C3%ADnez-Matsushita&amp;publication_year=2015&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20mutations%20in%20Mexican%20women%20with%20breast%20cancer&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=24&amp;pages=498" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> breast cancer, ovarian cancer, BRCA1, BRCA2, germline mutation</p><p><span>Citation:</span> Ferreyra Y, Rosas G, Cock-Rada AM, Araujo J, Bravo L, Doimi F, Casas J, Clavo Mdl&#xc1;, Pinto JA and Belmar-L&#xf3;pez C (2023) Landscape of germline <i>BRCA1/BRCA2</i> variants in breast and ovarian cancer in Peru. <i>Front. Oncol.</i> 13:1227864. doi: 10.3389/fonc.2023.1227864</p><p id="timestamps"><span>Received:</span> 23 May 2023; <span>Accepted:</span> 27 July 2023;<br><span>Published:</span> 17 August 2023.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/2020199">Charles Theillet</a>, Institut du Cancer de Montpellier (ICM), France</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/2333558">Ekaterina Kuligina</a>, N.N. Petrov National Medical Research Center of Oncology, Russia<br><a href="https://loop.frontiersin.org/people/558253">Alvaro Galli</a>, National Research Council (CNR), Italy</div><p><span>Copyright</span> &#xa9; 2023 Ferreyra, Rosas, Cock-Rada, Araujo, Bravo, Doimi, Casas, Clavo, Pinto and Belmar-L&#xf3;pez. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Joseph A. Pinto, <a id="encmail">anBpbnRvQGdlY29wZXJ1Lm9yZw==</a></p><div class="clear"></div></div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1227864" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">5,9K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2,1K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">8</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1227864#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2023.1227864" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2023.1227864" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/2020199/overview" data-event="editorInfo-a-charlesTheillet" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">C</span><span class="notranslate">T</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Charles  Theillet</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Institut du Cancer de Montpellier (ICM), France</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/558253/overview" data-event="editorInfo-a-alvaroGalli" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Alvaro  Galli</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Pisa Research Area, National Research Council (CNR), Italy</div></div></a><a href="https://loop.frontiersin.org/people/2333558/overview" data-event="editorInfo-a-ekaterinaKuligina" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">E</span><span class="notranslate">K</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Ekaterina  Kuligina</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">N.N. Petrov National Medical Research Center of Oncology, Russia</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Background</a></li><li><a href="#h3">Methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Data availability statement</a></li><li><a href="#h7">Ethics statement</a></li><li><a href="#h8">Author contributions</a></li><li><a href="#h9">Conflict of interest</a></li><li><a href="#h10">Publisher&#x2019;s note</a></li><li><a href="#h11">Supplementary material</a></li><li><a href="#h13">Abbreviations</a></li><li><a href="#h13">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1227864" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2023.1227864/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":860,"mainHeader":864},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":707,"currentArticlePageMetaInfo":708,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":543,"articleType":549,"stage":552,"keywords":554,"authors":560,"editors":635,"reviewers":645,"journal":664,"section":672,"impactMetrics":674,"volume":677,"articleVolume":678,"relatedArticles":679,"isPublishedV2":367,"contents":680,"files":684},1227864,"10.3389/fonc.2023.1227864","Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru",["Date","2023-07-27T06:09:15.000Z"],["Date","2023-05-23T20:23:06.000Z"],["Date","2023-08-17T00:00:00.000Z"],["Date","2025-11-25T03:15:22.663Z"],"There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors. The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar.. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied. We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G>T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c. 8023A>G (n=6,  16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG,  n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C>G (n=2), and for BRCA2, c.5465A>T (n=4), c.3101T>C (n=3), c.205C>A and c.437T>C (n=2). We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A>G. We found that BRCA2 c.8023A>G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.",{"id":544,"title":545,"articlesCount":546,"isMagazinePage":13,"slug":547,"isOpenForSubmission":367,"views":548},54586,"BRCA mutations and Homologous Recombination Deficiency (HRD) testing in ovarian cancer",8,"brca-mutations-and-homologous-recombination-deficiency-hrd-testing-in-ovarian-cancer",30110,{"id":550,"name":551},24,"Original Research",{"id":553,"name":19},18,[555,556,557,558,559],"breast cancer","ovarian cancer","BRCA1","BRCA2","germline mutation",[561,570,577,585,592,599,606,612,619,627],{"id":562,"firstName":563,"middleName":19,"lastName":564,"givenNames":565,"isCorresponding":367,"isProfilePublic":13,"userId":562,"email":-1,"affiliations":566},2212695,"Yomali","Ferreyra","Yomali ",[567],{"organizationName":568,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Departamento de Bioingeniera, Universidad de Ingenieria y Tecnologa","Peru",{"id":388,"firstName":571,"middleName":19,"lastName":572,"givenNames":573,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":574},"Gina","Rosas","Gina ",[575],{"organizationName":576,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Departamento de Patologa, Insituto Nacional de Enfermedades Neoplsicas",{"id":388,"firstName":578,"middleName":19,"lastName":579,"givenNames":580,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":581},"Alicia M.","Cock-Rada","Alicia M. ",[582],{"organizationName":583,"countryName":584,"cityName":19,"stateName":19,"zipCode":19},"Departmento de Oncologa Mdica, Instituto de Cancerologa Las Amricas - Auna","Colombia",{"id":388,"firstName":586,"middleName":19,"lastName":587,"givenNames":588,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":589},"Jhajaira","Araujo","Jhajaira ",[590],{"organizationName":591,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Centro de Investigacin Bsicas y traslacional",{"id":388,"firstName":593,"middleName":19,"lastName":594,"givenNames":595,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":596},"Leny","Bravo","Leny ",[597],{"organizationName":598,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista",{"id":388,"firstName":600,"middleName":19,"lastName":601,"givenNames":602,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":603},"Franco","Doimi","Franco ",[604],{"organizationName":605,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Oncogenomics, Auna",{"id":388,"firstName":607,"middleName":19,"lastName":608,"givenNames":609,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":610},"Jhoysi","Casas","Jhoysi ",[611],{"organizationName":605,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":613,"middleName":19,"lastName":614,"givenNames":615,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":616},"Mara de los ngeles","Clavo","Mara de los ngeles ",[617],{"organizationName":618,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga",{"id":620,"firstName":621,"middleName":19,"lastName":622,"givenNames":623,"isCorresponding":13,"isProfilePublic":13,"userId":620,"email":624,"affiliations":625},519797,"Joseph A.","Pinto","Joseph A. ","jpinto@gecoperu.org",[626],{"organizationName":591,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},{"id":628,"firstName":629,"middleName":19,"lastName":630,"givenNames":631,"isCorresponding":367,"isProfilePublic":13,"userId":628,"email":-1,"affiliations":632},1513359,"Carolina","Belmar-Lpez","Carolina ",[633,634],{"organizationName":598,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":605,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},[636],{"id":637,"firstName":638,"middleName":19,"lastName":639,"givenNames":640,"isCorresponding":367,"isProfilePublic":13,"userId":637,"email":-1,"affiliations":641},2020199,"Charles","Theillet","Charles ",[642],{"organizationName":643,"countryName":644,"cityName":19,"stateName":19,"zipCode":19},"Institut du Cancer de Montpellier (ICM)","France",[646,655],{"id":647,"firstName":648,"middleName":19,"lastName":649,"givenNames":650,"isCorresponding":367,"isProfilePublic":13,"userId":647,"email":-1,"affiliations":651},558253,"Alvaro","Galli","Alvaro ",[652],{"organizationName":653,"countryName":654,"cityName":19,"stateName":19,"zipCode":19},"Pisa Research Area, National Research Council (CNR)","Italy",{"id":656,"firstName":657,"middleName":19,"lastName":658,"givenNames":659,"isCorresponding":367,"isProfilePublic":13,"userId":656,"email":-1,"affiliations":660},2333558,"Ekaterina","Kuligina","Ekaterina ",[661],{"organizationName":662,"countryName":663,"cityName":19,"stateName":19,"zipCode":19},"N.N. Petrov National Medical Research Center of Oncology","Russia",{"id":115,"slug":117,"name":116,"shortName":665,"electronicISSN":666,"field":667,"specialtyId":28,"journalSectionPaths":670},"Front. Oncol.","2234-943X",{"id":668,"domainId":669},57,2,[671],{"section":672},{"id":120,"name":121,"slug":122,"specialtyId":673},1226,{"views":675,"downloads":676,"citations":546},5855,2138,13,"Volume 13 - 2023",[],{"titleHtml":681,"fullTextHtml":682,"menuHtml":683},"Landscape of germline \u003Ci>BRCA1/BRCA2\u003C/i> variants in breast and ovarian cancer in Peru","\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2212695\" class=\"user-id-2212695\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2212695/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Yomali Ferreyra\">Yomali Ferreyra\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Gina Rosas\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Gina Rosas\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Alicia M. Cock-Rada\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Alicia M. Cock-Rada\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jhajaira Araujo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jhajaira Araujo\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Leny Bravo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Leny Bravo\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Franco Doimi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Franco Doimi\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jhoysi Casas\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jhoysi Casas\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Mar&#xed;a de los &#xc;ngeles Clavo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Mar&#xed;a de los &#xc1;ngeles Clavo\u003Csup>7\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/519797\" class=\"user-id-519797\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/519797/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Joseph A. Pinto*\">Joseph A. Pinto\u003C/a>\u003Csup>4*\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1513359\" class=\"user-id-1513359\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1513359/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Carolina Belmar-L&#xf;pez,\">Carolina Belmar-L&#xf3;pez\u003C/a>\u003Csup>5,6\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Departamento de Bioingenier&#xed;a, Universidad de Ingenieria y Tecnolog&#xed;a, Lima, Peru\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Departamento de Patolog&#xed;a, Insituto Nacional de Enfermedades Neopl&#xe1;sicas, Lima, Peru\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Departmento de Oncolog&#xed;a M&#xe9;dica, Instituto de Cancerolog&#xed;a Las Am&#xe9;ricas - Auna, Medell&#xed;n, Colombia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Centro de Investigaci&#xf3;n B&#xe1;sicas y traslacional, Auna Ideas, Lima, Peru\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Ica, Peru\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Oncogenomics, Auna, Lima, Peru\u003C/li>\u003Cli>\u003Cspan>\u003Csup>7\u003C/sup>\u003C/span>Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga, Ica, Peru\u003C/li>\u003C/ul>\u003Cp>\u003Cb>Background:\u003C/b> There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate&#x2013;ribose) polymerase (PARP) inhibitors.\u003C/p>\u003Cp>\u003Cb>Methods:\u003C/b> The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied. \u003C/p>\u003Cp>\u003Cb>Results:\u003C/b> We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G&gt;T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c.8023A&gt;G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C&gt;G (n=2), and for BRCA2, c.5465A&gt;T (n=4), c.3101T&gt;C (n=3), c.205C&gt;A and c.437T&gt;C (n=2). \u003C/p>\u003Cp>\u003Cb>Conclusion:\u003C/b> We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A&gt;G. We found that BRCA2 c.8023A&gt;G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.2%.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Background\u003C/h2>\u003Cp class=\"mb15\">Breast and ovarian cancer are highly prevalent malignancies in Latin America, where more than 50 thousand patients die yearly from these pathologies. It is estimated that 5-10% of breast cancer (BC) and 10-15% of ovarian cancer (OC) are attributed to hereditary breast and ovarian cancer (HBOC). Mutations in the \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes are the best-known genetic risk factors for breast and ovarian cancer (\u003Ca href=\"#B1\">1\u003C/a>&#x2013;\u003Ca href=\"#B3\">3\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Detecting \u003Ci>BRCA1/2\u003C/i> mutations allows crucial and challenging decisions regarding cancer prevention or risk reduction, early detection and pharmacological management. Germline \u003Ci>BRCA1/2\u003C/i> variants cause hereditary breast and ovarian cancer syndrome and confer a lifetime risk of 38-87% of developing breast cancer in women and 16.5-63% of developing ovarian cancer (\u003Ca href=\"#B4\">4\u003C/a>). Germline \u003Ci>BRCA1/2\u003C/i> mutations are present in approximately 5% of all breast patients and 15% of all ovarian cancer patients (\u003Ca href=\"#B5\">5\u003C/a>, \u003Ca href=\"#B6\">6\u003C/a>). Breast tumors with \u003Ci>BRCA1/2\u003C/i> mutation carriers are more frequently HER2 negative, and triple-negative tumors (TNBC) account for approximately 68% of \u003Ci>BRCA1\u003C/i> tumors (\u003Ca href=\"#B7\">7\u003C/a>). High-grade serous ovarian cancers are more commonly associated with \u003Ci>BRCA1/2\u003C/i> mutations (\u003Ca href=\"#B8\">8\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">\u003Ci>BRCA1/2\u003C/i> are tumor suppressor genes that participate in the homologous recombination repair of double-strand DNA damage. \u003Ci>BRCA1/2\u003C/i> defective cells are more sensitive to Poly(ADP-ribose) polymerase (PARP), an enzyme involved in base excision repair, a vital component of single-strand break repair (SSB). PARP inhibitors can increase SSB, which are converted to double-strand DNA breaks (DSBs) during replication. In defective \u003Ci>BRCA1/2\u003C/i> cells, these DSBs are not effectively repaired, leading to chromosomal instability, cell cycle arrest, and subsequent apoptosis, a mechanism known as synthetic lethality (\u003Ca href=\"#B9\">9\u003C/a>)\u003C/p>\u003Cp class=\"mb15\">Several PARP inhibitors have been developed to treat patients with breast, ovarian, pancreatic, and prostate cancer with \u003Ci>BRCA1/2\u003C/i> mutations. OlympiAD, a phase III randomized, controlled, open-label study trial, compared Olaparib, a PARP inhibitor, with non-platinum chemotherapy (CT) in metastatic breast cancer patients with germline \u003Ci>BRCA\u003C/i>1/2 mutations. Progression-free survival (PFS) was higher in patients receiving Olaparib than in those receiving CT (7.0 vs 2.2 months). The hazard ratio (HR) for disease progression or death was 0.58 (95% CI 0.43-0.80: P&lt; 0.001). The response rate was 59.9% in the Olaparib group and 28.8% in the CT group. An improvement in PFS was observed in all subtypes and was higher in TNBC patients (\u003Ca href=\"#B10\">10\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The randomized phase III trial, EMBRACA, compared another PARP inhibitor, Talazoparib, with single-agent CT in patients with advanced breast cancer with \u003Ci>BRCA1/2\u003C/i> mutations. The median PFS was longer in the Talazoparib group than in the control group (8.6 months [95% CI, 7.2-9.3] vs 5.6 months [95% CI, 4.2-6.7]; HR=0.54 [95% CI 0.41-0.71; P &lt; 0.001] for disease progression or death. Based on these two trials, the FDA approved Olaparib and Talozaparib for HER2-negative patients with \u003Ci>BRCA1/2\u003C/i> mutations, and the NCCN guidelines recommend testing for \u003Ci>BRCA1/2\u003C/i> mutations in all patients with TNBC or metastatic breast cancer to identify candidates for PARP inhibitor therapy (\u003Ca href=\"#B11\">11\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">For ovarian cancer, germline testing for \u003Ci>BRCA\u003C/i>1/2 is informative for selecting patients for PARP inhibitor therapy. Around 50% of ovarian tumors are homologous recombination deficient (HRD) and 20% are associated with \u003Ci>BRCA1/2\u003C/i> mutations, germline (14%) or somatic (6%) (\u003Ca href=\"#B6\">6\u003C/a>). PARP inhibitor treatment is recommended for maintenance therapy for stage II-IV disease or persistent or recurrent disease in BRCA\u003Ci>1/2\u003C/i> mutated ovarian cancer (\u003Ca href=\"#B12\">12\u003C/a>). The SOLO-1 phase III trial showed an improvement in 3-year PFS with Olaparib versus Placebo as maintenance therapy for patients with a germline \u003Ci>variant BRCA1/2\u003C/i>, who had a complete or partial response (CR/PR) after platinum-based first-line chemotherapy (60% vs. 27%; P&lt;0.0001); HR=0.30 [95% CI, 0.23-0.41] (\u003Ca href=\"#B13\">13\u003C/a>). Other phase III studies with PARP inhibitor, PAOLA-1: Olaparib + Bevacizumab versus Placebo + Bevacizumab for maintenance therapy for patients with advanced disease who had CR/PR after platinum-based first-line chemotherapy, or PRIMA: Niraparib versus Placebo as maintenance therapy for patients with CR/PR after platinum first-line chemotherapy showed a notable improvement in median PFS, especially in patients with a germline \u003Ci>BRCA\u003C/i>1/2 mutation or HRD (22.1 vs 16.6 months and 21.9 months vs 10.4 months, respectively) (\u003Ca href=\"#B14\">14\u003C/a>, \u003Ca href=\"#B15\">15\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">There is increasing information on the molecular epidemiology of \u003Ci>BRCA1/2\u003C/i> genes in Latin America and several founder mutations have been identified (\u003Ca href=\"#B16\">16\u003C/a>). Founder mutations in Latin America have been reported in Mexico (\u003Ci>BRCA1\u003C/i> del exons 9-12), Brazil (\u003Ci>BRCA1\u003C/i> 5382insC and \u003Ci>BRCA2\u003C/i> c.156_157insAlu), and Colombia (\u003Ci>BRCA1\u003C/i> 3450del4, A1708E and \u003Ci>BRCA2\u003C/i> 3034del4) (\u003Ca href=\"#B17\">17\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">Unfortunately, there is a gap in information about the genetic epidemiology of breast and ovarian cancers in Peru. A limited number of publications describe the frequency of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations in Peru with studies with small sample sizes and in a particular group of patients (\u003Ca href=\"#B18\">18\u003C/a>). Here, we describe the frequency and spectrum of genetic variants (pathogenic/likely pathogenic P/LP and VUS) in \u003Ci>the BRCA1/2\u003C/i> genes in patients with BC and/or OC, profiled during 2019-2021 in a reference laboratory in Peru, for the identification of PARP inhibitor candidates.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Methods\u003C/h2>\u003Ch3>Study population\u003C/h3>\u003Cp class=\"mb0\">The study included all BC and OC patients, referred to Oncogenomics Laboratory (Lima, Peru) from 2019 to 2021, to identify candidates for PARP inhibitors treatment. The histological tumor types, hormone receptor and human epidermal growth factor receptor 2 (HER2) statuses were recorded.\u003C/p>\u003Ch3>\u003Ci>BRCA1/2\u003C/i> mutation screening\u003C/h3>\u003Cp class=\"mb0\">Peripheral blood samples were taken to assess mutations in \u003Ci>the BRCA1/2\u003C/i> genes. DNA was extracted using the ReliaPrep Blood gDNA Miniprep System or the ReliaPrep FFPE gDNA Miniprep System (Promega, Madison, USA) according to the manufacturer&#x2019;s protocol. DNA concentration was determined by fluorometric quantitation using a Qubit 4.0 fluorimeter with Qubit dsDNA HS ASSAY KIT (Invitrogen, USA). The panel targets single nucleotide variants (SNVs) and insertion/deletions (indels) in all exonic regions of the \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes and flanking intronic sequences. A commercial reference standard, Horizon Quantitative Multiplex Reference Standard HD810 was tested to validate the performance of NGS that detect mutations. Libraries were prepared using the Ampliseq \u003Ci>BRCA\u003C/i> Panel and Ampliseq Library PLUS (Illumina, San Diego, USA) following the manufacturer&#x2019;s protocol without modifications using 10 ng of input DNA per sample. The multiplex polymerase chain reaction (PCR) was performed in 18 cycles. Sequencing adapters with unique indexes (AmpliSeq CD Indexes Set A for Illumina) were ligated to the amplification products and purified using Agencourt AmpureXP beads (Beckman Coulter, CA, USA) according to the manufacturer&#x2019;s instructions. Libraries with 2nM molarities were subjected to clustering using a standard flow cell and sequenced on the Illumina MiSeq platform using the MiSeq Reagent Micro Kit v2 (300 cycles). Raw data were processed automatically in the BaseSpace Sequence Hub (Illumina) and aligned with the hg19 reference genome. An average of 95.7% (91.7&#x2013; 99.8%) on-target reads, 96.6% (94.7 &#x2013; 98.6%) read uniformity and 50X average coverage per sample were obtained.\u003C/p>\u003Ch3>Mutation nomenclature and classification\u003C/h3>\u003Cp class=\"mb15\">BaseSpace Variant Interpreter (Illumina) annotated and interpreted genetic variants. Genetic variants were annotated under the nomenclature of the Human Genome Variation Society (HGVS). Interpretation was made using the single nucleotide polymorphism database (dbSNP), breast cancer information core (BIC) and Clinvar database. The Integrative Genomics Viewer was applied to visualize the variants. All identified variants were checked with Varsome (Saphetor, Swiss).\u003C/p>\u003Cp class=\"mb0\">Interpreting the pathogenicity of the variants followed the latest recommendations of the American College of Medical Genetics (ACMG) and ClinVar. In cases of conflicting interpretations of pathogenicty (classified as pathogenic by at least one database and benign, likely benign, or VUS by others) between ACMG and ClinVar, ACMG classification was used. All new variants (missense, in frame and splicing) not yet reported in the databases consulted, were also considered VUS. Benign variants were not reported.\u003C/p>\u003Ch3>Statistical analysis\u003C/h3>\u003Cp class=\"mb0\">We conducted a descriptive analysis. The frequency of variants identified in the \u003Ci>BRCA1/2\u003C/i> genes was calculated using RStudio. Packages such as \u003Ci>sf, ggplot2\u003C/i> and \u003Ci>ggrepel\u003C/i> were installed to obtain geographical maps of Peru, to observe the distribution of pathogenic variants according to the place of birth of the patients.\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3>General characteristics of patients\u003C/h3>\u003Cp class=\"mb0\">A total of 525 patients were included in this study (143 with BC and 382 with OC). Most of the patients were born in metropolitan Lima (58.1%), followed by patients from the coast (excluding metropolitan Lima, 28.0%), highlands (11.6%) and jungle (2.1%). Regarding the clinical characteristics of BC patients, 21.7% (n=31) had HER2-negative and hormone receptor positive tumors, while 78.3% (n=112) of the patients had HER2-negative and hormone receptor negative tumors (TNBC). Most of the OC (90.8%) were high-grade serous carcinomas. The frequency of clinical stage III was 33.6% and 50%, and clinical stage IV was 66.4% and 50% for BC and OC, respectively (\u003Ca href=\"#T1\">Table 1\u003C/a>). The prevalence of patients with P/LP germline variants in \u003Ci>BRCA1/2\u003C/i> was 19.0% (n=100/525). No patient had more than one P/LP variant. The percentage of BC patients who carried germline \u003Ci>BRCA1/2\u003C/i> P/LP variants was 14.7% (n=21/143) with 61.9% (n=13/21) of them carrying variants in \u003Ci>BRCA1\u003C/i> and 38.1% (n=8/21) in \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#f1\">Figure&#xa0;1\u003C/a>). In total, 81% (n=17/21) of patients with \u003Ci>BRCA1/2\u003C/i> P/LP variants were TNBC and 19.1% (n=4/21) were positive for hormone receptors. Furthermore, 38.1% (n=8/21) were reported in clinical stage III and 61.9% (n=13/21) in clinical stage IV. Although we had no information about their age at the time of diagnosis, the mean age at molecular diagnosis was 48.63 years (range: 30-74 years).On the other hand, 20.7%(n=79/382) of OC patients had germline \u003Ci>BRCA1/2\u003C/i> P/LP variants with 64.8% (n=51/79) of them in \u003Ci>BRCA1\u003C/i> and 35.44% (n=28/79) in \u003Ci>BRCA2\u003C/i>. Regarding the histological subtypes of \u003Ci>BRCA1/2\u003C/i> OC patients, it was observed that 91.1% (n=72/79) were characterized by high-grade serous carcinoma, followed by endometrioid carcinoma (n=5/79, 6.3%) and clear cell carcinoma (n=2/79, 2.53%). The clinical stages were distributed in 49.4% (n=39/79) stage III and 50.6% (n=40/79) stage IV. Furthermore, only 77 patients had their age at molecular diagnosis available, so the mean age was 54.36 years (range: 34-77).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" name=\"table&#xa0;1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;1\u003C/b> Clinicopathological characteristics of the general population.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;1\u003C/b> Flowchart showing results and characteristics of patients with breast and ovarian cancer included in this study. P/LP, Pathogenic/likely pathogenic.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Germline \u003Ci>BRCA1\u003C/i> pathogenic/likely pathogenic variants\u003C/h3>\u003Cp class=\"mb0\">The study identified 33 different P/LP germline variants in \u003Ci>BRCA1\u003C/i> gene in 64 patients, finding 20.3% (n=13/64) in BC and 79.9% (n=51/64) in OC. The most frequent variants in \u003Ci>BRCA1\u003C/i> were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G&gt;T and c.815 _824dupAGCCATGTGG (n=5, 7.81%) (\u003Ca href=\"#T2\">Table&#xa0;2\u003C/a>). Most variants were previously reported, except \u003Ci>BRCA1\u003C/i> c.2344dupA (n=2, 2.74%), which was not reported in any database. These patients were born in Lima and Arequipa.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" name=\"table&#xa0;2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;2\u003C/b> Pathogenic/likely pathogenic germline \u003Ci>BRCA1\u003C/i> variants found in our study.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">Furthermore, \u003Ci>BRCA1\u003C/i> P/LP variants were observed mainly in exon 10 (n=20/33), exon 19 (n = 3/33), and exon 2 and 4 (n=2/33). Most of the P/LP variants were missense (n=13/33) and in frame deletion variants (n=12/33), followed by frame insertions (n=6/33) and stop gained variants (n=1/33) (\u003Ca href=\"#T2\">Table&#xa0;2\u003C/a>). There was only one case with a large deletion, specifically a deletion of exon 11 (n=1/33). Patients with P/LP variants in the \u003Ci>BRCA1\u003C/i> gene were born primarily in Metropolitan Lima (n=37/64), the coast (n=21/64) and the highlands (n=6/64). The most frequent P/LP variants in \u003Ci>BRCA1\u003C/i>, c.2105dupT (n=11) and c.68_69delAG (n=5) were found predominantly in patients born in Metropolitan Lima (\u003Ca href=\"#f2\">Figure&#xa0;2A\u003C/a>). The position of P/LP variants in relation to the Brca1 protein is shown in \u003Ca href=\"#f3\">Figure&#xa0;3A\u003C/a>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;2\u003C/b> Pathogenic/likely pathogenic germline \u003Ci>BRCA1/2\u003C/i> variants according to the place of birth \u003Cb>(A)\u003C/b> Germline \u003Ci>BRCA1\u003C/i> LP/P variants \u003Cb>(B)\u003C/b> Germline \u003Ci>BRCA2\u003C/i> LP/P variants.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;3\u003C/b> Maps presenting counts of pathogenic and likely pathogenic variants sites in \u003Cb>(A)\u003C/b> Brca1 and \u003Cb>(B)\u003C/b> Brca2 proteins.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Germline \u003Ci>BRCA2\u003C/i> pathogenic/likely pathogenic variants\u003C/h3>\u003Cp class=\"mb0\">We found 22 different P/LP variants in \u003Ci>BRCA2\u003C/i> among 36 patients, 22.2% (n=8/36) in BC and 77.8% (n=28/36) in OC. The most frequent mutations in \u003Ci>BRCA2\u003C/i> were c.8023A&gt;G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%) (\u003Ca href=\"#T3\">Table&#xa0;3\u003C/a>). Likewise, most of the \u003Ci>BRCA2\u003C/i> P/LP variants were found only in OC patients (n=14/22, 63.63%), followed by both OC and BC patients (n=4/22, 18.18%) and only BC patients (n=4/22, 18.18%). Furthermore, \u003Ci>BRCA2\u003C/i> variants were mainly reported in exon 11 (n=9/22, 40.91%), predominantly inframe deletions (n=10/22), followed by inframe insertions (n=6/22) and missense variants (n=5/22) (\u003Ca href=\"#T3\">Table&#xa0;3\u003C/a>). Only one large deletion was identified in exon 10. Patients with P/LP variations in \u003Ci>BRCA2\u003C/i> were born in Metropolitan Lima (n = 24/36), on the coast (n=9/36) and in the highlands (n=3/36) (\u003Ca href=\"#f2\">Figure&#xa0;2B\u003C/a>). The position of P/LP variants in relation to the Brca\u003Ci>2\u003C/i> protein is shown in \u003Ca href=\"#f3\">Figure&#xa0;3B\u003C/a>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" name=\"table&#xa0;3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;3\u003C/b> Pathogenic/likely pathogenic germline \u003Ci>BRCA2\u003C/i> variants found in our study.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>BRCA1/2 germline VUS\u003C/h3>\u003Cp class=\"mb0\">\u003Ci>BRCA1/2\u003C/i> variants classified as VUS were found in 7.23% (n=38/525) of the total study population. Regarding \u003Ci>BRCA1\u003C/i>, eight different VUS were found, with an overall frequency in patients of 1.71% (n = 9/525). Most VUS were reported only in patients with OC (n= 7/8, 87.5%) with a low frequency per variant (n=1/9, 1.1%) and most of them occurred in exon 10. Two VUS had conflicting classifications between ClinVar and the ACMG guidelines: \u003Ci>BRCA1\u003C/i> c.93C&gt;G (n = 2/9, 2.22%) and \u003Ci>BRCA1\u003C/i> c.287A&gt;G (\u003Ca href=\"#h10\">Table S1\u003C/a>). The overall frequency of VUS in \u003Ci>BRCA2\u003C/i> was 5.52% (n=29/525). We identified 21 different VUS in \u003Ci>BRCA2\u003C/i> and the most frequent were c.5465A&gt;T (n = 4, 13.79%), followed by c.3101T&gt;C (n = 3, 10.34%), c.205C&gt;A and c.437T&gt;C (n = 2, 6.89%). Similarly, many of the VUS occurred in exon 11 (n = 9/21, 42.86%) and were reported only in patients with OC (n = 14/21, 66.67%). Variants c.2274T&gt;G, c.3509C&gt;T, c.7617 + 6T&gt;C, c.7759C&gt;T, and c.8462T&gt;C had conflicting classifications between the ACMG guidelines and ClinVar (\u003Ca href=\"#h10\">Table S1\u003C/a>). In addition the pathogenic scores of VUS founds in this study are also presented in \u003Ca href=\"#h10\">Table S1\u003C/a>.\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">Breast and ovarian cancers are malignancies with a high incidence and prevalence in Latin American women. Costs of treatment and disability adjusted life years directly impact public health systems and society. The management of BC and OC is rapidly evolving with the discovery of new treatments that offer an improved survival advantage, as seen in recent years with PARP inhibitors in \u003Ci>BRCA1/2\u003C/i> mutation carriers (\u003Ca href=\"#B19\">19\u003C/a>)\u003C/p>\u003Cp class=\"mb15\">There is limited information on the molecular epidemiology of BRCA1/2 in Peru. Although a third of the Peruvian population lives in Lima, there are economic and geographic barriers that make it difficult for patients to access adequate cancer care, including molecular tests and genetic counseling (\u003Ca href=\"#B20\">20\u003C/a>). Our work has some limitations, for example, the underrepresentation of patients from several regions of Peru, which have socioeconomic and ancestry differences with respect to Lima. Another limitation that could cause bias is that the study population was selected for possible treatment with PARP inhibitors (e.g., advanced-stage cancer, HER2-negative breast cancer).\u003C/p>\u003Cp class=\"mb15\">The study of \u003Ci>BRCA1/2\u003C/i> variants in these patients is crucial to identify candidates for these treatments, but is also important to manage their future cancer risks. Patients with \u003Ci>BRCA1/2\u003C/i> mutations and their families can benefit from cancer risk reduction or early cancer detection strategies, such as double mastectomy or high-risk follow-up for BC and bilateral salpingo-oophorectomy for OC (\u003Ca href=\"#B12\">12\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Latin American countries usually have less infrastructure and resources for genetic testing and treatment of patients with \u003Ci>BRCA1/2\u003C/i> than developed countries, and many of the cancer drugs approved in other countries are not available (\u003Ca href=\"#B21\">21\u003C/a>). Therefore, genetic testing is not always performed when needed. The interpretation of genetic variants can be more difficult in less-studied populations, and there are no specific open databases for variants in cancer-predisposing genes in Hispanic patients.\u003C/p>\u003Cp class=\"mb15\">\u003Ci>BRCA1\u003C/i> c.2105dupT was the most frequently found variant in this study. It is located in the coding exon 10 and causes a translational frameshift with a predicted alternate stop codon. This alteration is expected to result in loss of function, according to ClinVar. Until now, this variant was previously reported in 6 of 44 (13.6%) mutated patients with ovarian cancer belonging to the Peruvian population. Furthermore, it was reported only once in the Canadian population. A similar variant, \u003Ci>BRCA1\u003C/i> c.2105dup, was identified in Caucasian and Hispanic individuals in a study that included only female carriers with pathogenic variants in \u003Ci>BRCA1\u003C/i>/2 \u003Ci>(\u003C/i>\u003Ca href=\"#B22\">22\u003C/a>)\u003C/p>\u003Cp class=\"mb15\">In our cohort, we observed the \u003Ci>BRCA1\u003C/i> c.68_69delAG mutation (185delAG), which occurs in exon 2 and creates a stop codon at position 39. This alteration leads to premature translation termination and significant protein truncation (\u003Ca href=\"#B23\">23\u003C/a>). Regarding its origin, it constitutes one of the primary founder mutations in the Ashkenazi Jewish population that arose 61 generations ago and was introduced into the Hispanic population 650 years ago (\u003Ca href=\"#B24\">24\u003C/a>). Currently, it has been reported among several other non-Jewish ethnic groups, such as Peruvians, Mexicans, Colombians, and Brazilians (\u003Ca href=\"#B25\">25\u003C/a>&#x2013;\u003Ca href=\"#B28\">28\u003C/a>). A study in Peruvian patients diagnosed with breast cancer showed that 185delAG was the most common mutation found, observed in 7 of 13 carriers (54%). They also noted that two mutation carriers identified as of indigenous ancestry had the \u003Ci>BRCA1\u003C/i> 185delAG mutation (\u003Ca href=\"#B28\">28\u003C/a>). Unlike that study, we found that the mutation was observed in people born in Lima and Lambayeque. While it has not been determined whether they share an indigenous or Jewish ancestry, it is known that although the 185delAG mutation resides in a common haplotype among Ashkenazi Jews, it also arose independently in at least two non-Jewish populations, such as those in Malaysia and the United Kingdom. On the other hand, the \u003Ci>BRCA1\u003C/i> c.140G&gt;T mutation is a missense variant, which occurs within exon 5 and the RING domain. It was previously reported as a VUS in Peruvian families with hereditary breast and ovarian cancer (\u003Ca href=\"#B18\">18\u003C/a>, \u003Ca href=\"#B24\">24\u003C/a>). However, it was also identified in the Norwegian population as a pathogenic and non-founder mutation (\u003Ca href=\"#B29\">29\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">The \u003Ci>BRCA1\u003C/i> c.815_824dupAGCCATGTGG variant is located in exon 10 and is the most common pathogenic variant reported in African Americans (\u003Ca href=\"#B30\">30\u003C/a>). This pathogenic variant results in a frameshift and a spurious stop codon of 14 amino acids downstream. Due to its African origin, the variant was found in inherited patients with BC from Senegal and its allele frequency was 27.7%. In that study, the variant was also detected in a control population of sporadic BC cases and healthy controls without cancer (allele frequency estimated at 5% and 0.55%, respectively) (\u003Ca href=\"#B31\">31\u003C/a>). This variant was also found in Latin American populations, such as Colombian, Peruvian and Mexican (\u003Ca href=\"#B18\">18\u003C/a>, \u003Ca href=\"#B32\">32\u003C/a>, \u003Ca href=\"#B33\">33\u003C/a>). In \u003Ca href=\"#T4\">Table&#xa0;4\u003C/a>, we summarize and compare our findings with those of other populations. Because we evaluated a very specific group of patients, comparison of prevalence of P/LP variants with other populations it would not be appropriate.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" name=\"table&#xa0;4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-t004.jpg\" alt=\"www.frontiersin.org\" id=\"T4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;4\u003C/b> Previous reports of \u003Ci>BRCA1/2\u003C/i> variants found in this study in different populations.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">In conclusion, in this selected Peruvian population, we found a frequency of 14.7% \u003Ci>BRCA1/2\u003C/i> germline mutations in BC and 20.7% in OC. The most recurrent mutations were \u003Ci>BRCA1\u003C/i> c.2105dupT and BRCA2 c.8023A&gt;G. On the other hand, BRCA2 c.8023A&gt;G, c.6024dupG and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Data availability statement\u003C/h2>\u003Cp class=\"mb0\">The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/\u003Ca href=\"#h10\">Supplementary Material\u003C/a>.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Ethics statement\u003C/h2>\u003Cp class=\"mb0\">The study was approved by the Institutional Review Board of the Universidad Privada San Juan Bautista (418-2021-CIEI-UPSJB) and conducted in compliance with all relevant ethical guidelines. Due to the retrospective nature of the study, the informed consent was waived.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Author contributions\u003C/h2>\u003Cp class=\"mb15\">CB-L, JC, and FD conducted molecular assays and collected the data. CB-L, FD, YF, GR, and AC-R conducted analysis of variants. YF, GR, JA, LB, and JP conducted statistical analysis. MC conducted the bioinformatic analysis. YF, GR, JA, LB, and JP prepared \u003Ca href=\"#T1\">Tables&#xa0;1\u003C/a>, \u003Ca href=\"#T2\">2\u003C/a>. YF, GR, JA, LB, and JP prepared \u003Ca href=\"#f1\">Figures&#xa0;1\u003C/a>-\u003Ca href=\"#f3\">3\u003C/a>. All authors wrote the manuscript. All authors contributed to the article and approved the submitted version.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Conflict of interest\u003C/h2>\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Publisher&#x2019;s note\u003C/h2>\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Supplementary material\u003C/h2>\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2023.1227864/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2023.1227864/full#supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Abbreviations\u003C/h2>\u003Cp class=\"mb15\">VUS, Variants of Uncertain/Unknown Significance; PARP, Poly (Adenosine Diphosphate&#x2013;Ribose) Polymerase; BC, Breast Cancer; OC, Ovarian Cancer; HBOC, Hereditary Breast and Ovarian Cancer; SSB, single-strand break repair, DSBs, Double-Strand DNA Breaks; CT, Chemotherapy; PFS, Progression-free survival; TNBC, Triple Negative Patients; CR/PR, Complete or Partial Response; HRD, Homologous Recombination Deficient; HER2, Human Epidermal Growth Factor Receptor 2; P/PL, Pathogenic/Likely Pathogenic; SNVs, Single Nucleotide Variants; PCR, Polymerase Chain Reaction; HGVS, Human Genome Variation Society (HGVS); dbSNP, Single Nucleotide Polymorphism Database; BIC, Breast Cancer Information Core; ACMG, American College of Medical Genetics.\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. \u003Ci>CA Cancer J Clin\u003C/i> (2021) 71(3):209&#x2013;49. doi: 10.3322/caac.21660\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33538338/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21660\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Sung&amp;author=J+Ferlay&amp;author=RL+Siegel&amp;author=M+Laversanne&amp;author=I+Soerjomataram&amp;author=A+Jemal&amp;publication_year=2021&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA+Cancer+J+Clin&amp;volume=71&amp;pages=209-49\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. \u003Ci>Breast Cancer\u003C/i> (2021) 28(6):1167&#x2013;80. doi: 10.1007/s12282-020-01148-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32862296/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s12282-020-01148-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Yoshida&amp;publication_year=2021&amp;title=Hereditary%20breast%20and%20ovarian%20cancer%20%28HBOC%29%3A%20review%20of%20its%20molecular%20characteristics%2C%20screening%2C%20treatment%2C%20and%20prognosis&amp;journal=Breast+Cancer&amp;volume=28&amp;pages=1167-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Saleem M, Ghazali MB, Wahab MAMA, Yusoff NM, Mahsin H, Seng CE, et al. The BRCA1 and BRCA2 genes in early-onset breast cancer patients. \u003Ci>Adv Exp Med Biol\u003C/i> (2020) 1292:1&#x2013;12. doi:&#xa0;10.1007/5584_2018_147\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29687286/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/5584_2018_147\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Saleem&amp;author=MB+Ghazali&amp;author=MAMA+Wahab&amp;author=NM+Yusoff&amp;author=H+Mahsin&amp;author=CE+Seng&amp;publication_year=2020&amp;title=The%20BRCA1%20and%20BRCA2%20genes%20in%20early-onset%20breast%20cancer%20patients&amp;journal=Adv+Exp+Med+Biol&amp;volume=1292&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Petrucelli N, Daly MB, Pal T. \u003Ci>BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer\u003C/i> (2022). GeneReviews&#xae;. Available at: \u003Ca href=\"https://www.ncbi.nlm.nih.gov/books/NBK1247/\">https://www.ncbi.nlm.nih.gov/books/NBK1247/\u003C/a> (Accessed cited 2023 Jul 11).\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Petrucelli&amp;author=MB+Daly&amp;author=T+Pal&amp;publication_year=2022&amp;journal=BRCA1-+and+BRCA2-Associated+Hereditary+Breast+and+Ovarian+Cancer&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. \u003Ci>Cancer Res\u003C/i> (2006) 66(16):8297&#x2013;308. doi: 10.1158/0008-5472.CAN-06-0503\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16912212/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/0008-5472.CAN-06-0503\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KE+Malone&amp;author=JR+Daling&amp;author=DR+Doody&amp;author=L+Hsu&amp;author=L+Bernstein&amp;author=RJ+Coates&amp;publication_year=2006&amp;title=Prevalence%20and%20predictors%20of%20BRCA1%20and%20BRCA2%20mutations%20in%20a%20population-based%20study%20of%20breast%20cancer%20in%20white%20and%20black%20American%20women%20ages%2035%20to%2064%20years&amp;journal=Cancer+Res&amp;volume=66&amp;pages=8297-308\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D&#x2019;Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. \u003Ci>Cancer Discovery\u003C/i> (2015) 5(11):1137&#x2013;54. doi: 10.1158/2159-8290.CD-15-0714\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26463832/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/2159-8290.CD-15-0714\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PA+Konstantinopoulos&amp;author=R+Ceccaldi&amp;author=GI+Shapiro&amp;author=AD+D%E2%80%99Andrea&amp;publication_year=2015&amp;title=Homologous%20recombination%20deficiency%3A%20exploiting%20the%20fundamental%20vulnerability%20of%20ovarian%20cancer&amp;journal=Cancer+Discovery&amp;volume=5&amp;pages=1137-54\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). \u003Ci>Cancer Epidemiol Biomarkers Prev\u003C/i> (2012) 21(1):134&#x2013;47. doi: 10.1158/1055-9965.EPI-11-0775\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22144499/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.EPI-11-0775\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Mavaddat&amp;author=D+Barrowdale&amp;author=IL+Andrulis&amp;author=SM+Domchek&amp;author=D+Eccles&amp;author=H+Nevanlinna&amp;publication_year=2012&amp;title=Pathology%20of%20breast%20and%20ovarian%20cancers%20among%20BRCA1%20and%20BRCA2%20mutation%20carriers%3A%20results%20from%20the%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%2F2%20%28CIMBA%29&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=21&amp;pages=134-47\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. \u003Ci>Hum Mol Genet\u003C/i> (2014) 23(17):4703&#x2013;9. doi: 10.1093/hmg/ddu172\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24728189/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/ddu172\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=MS+Cicek&amp;author=E+Dicks&amp;author=P+Harrington&amp;author=SJ+Ramus&amp;author=JM+Cunningham&amp;publication_year=2014&amp;title=The%20contribution%20of%20deleterious%20germline%20mutations%20in%20BRCA1%2C%20BRCA2%20and%20the%20mismatch%20repair%20genes%20to%20ovarian%20cancer%20in%20the%20population&amp;journal=Hum+Mol+Genet&amp;volume=23&amp;pages=4703-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Farmer H, McCabe H, Lord CJ, Tutt AHJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. \u003Ci>Nature\u003C/i> (2005) 434(7035):917&#x2013;21. doi: 10.1038/nature03445\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15829967/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature03445\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Farmer&amp;author=H+McCabe&amp;author=CJ+Lord&amp;author=AHJ+Tutt&amp;author=DA+Johnson&amp;author=TB+Richardson&amp;publication_year=2005&amp;title=Targeting%20the%20DNA%20repair%20defect%20in%20BRCA%20mutant%20cells%20as%20a%20therapeutic%20strategy&amp;journal=Nature&amp;volume=434&amp;pages=917-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. \u003Ci>N Engl J Med\u003C/i> (2017) 377(6):523&#x2013;33. doi: 10.1056/NEJMoa1706450\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28578601/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1706450\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Robson&amp;author=SA+Im&amp;author=E+Senkus&amp;author=B+Xu&amp;author=SM+Domchek&amp;author=N+Masuda&amp;publication_year=2017&amp;title=Olaparib%20for%20metastatic%20breast%20cancer%20in%20patients%20with%20a%20germline%20BRCA%20mutation&amp;journal=N+Engl+J+Med&amp;volume=377&amp;pages=523-33\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon&#xe7;alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. \u003Ci>New Engl J Med\u003C/i> (2018) 379(8):753&#x2013;63. doi:&#xa0;10.1056/nejmoa1802905\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30110579/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/nejmoa1802905\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JK+Litton&amp;author=HS+Rugo&amp;author=J+Ettl&amp;author=SA+Hurvitz&amp;author=A+Gon%C3%A7alves&amp;author=KH+Lee&amp;publication_year=2018&amp;title=Talazoparib%20in%20patients%20with%20advanced%20breast%20cancer%20and%20a%20germline%20BRCA%20mutation&amp;journal=New+Engl+J+Med&amp;volume=379&amp;pages=753-63\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. \u003Ci>J Natl Compr Canc Netw\u003C/i> (2022) 20(6):691&#x2013;722. doi:&#xa0;10.6004/jnccn.2022.0030\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35714673/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.6004/jnccn.2022.0030\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WJ+Gradishar&amp;author=MS+Moran&amp;author=J+Abraham&amp;author=R+Aft&amp;author=D+Agnese&amp;author=KH+Allison&amp;publication_year=2022&amp;title=Breast%20cancer%2C%20version%203.2022%2C%20NCCN%20clinical%20practice%20guidelines%20in%20oncology&amp;journal=J+Natl+Compr+Canc+Netw&amp;volume=20&amp;pages=691\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. \u003Ci>N Engl J Med\u003C/i> (2018) 379(26):2495&#x2013;505. doi: 10.1056/NEJMoa1810858\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30345884/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1810858\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Moore&amp;author=N+Colombo&amp;author=G+Scambia&amp;author=BG+Kim&amp;author=A+Oaknin&amp;author=M+Friedlander&amp;publication_year=2018&amp;title=Maintenance%20olaparib%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer&amp;journal=N+Engl+J+Med&amp;volume=379&amp;pages=2495-505\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Ray-Coquard I, Pautier P, Pignata S, P&#xe9;rol D, Gonz&#xe1;lez-Mart&#xed;n A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. \u003Ci>New Engl J Med\u003C/i> (2019) 381(25):2416&#x2013;28. doi:&#xa0;10.1056/nejmoa1911361\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31851799/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/nejmoa1911361\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Ray-Coquard&amp;author=P+Pautier&amp;author=S+Pignata&amp;author=D+P%C3%A9rol&amp;author=A+Gonz%C3%A1lez-Mart%C3%ADn&amp;author=R+Berger&amp;publication_year=2019&amp;title=Olaparib%20plus%20bevacizumab%20as%20first-line%20maintenance%20in%20ovarian%20cancer&amp;journal=New+Engl+J+Med&amp;volume=381&amp;pages=2416-28\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Gonz&#xe1;lez-Mart&#xed;n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. \u003Ci>New Engl J Med\u003C/i> (2019) 381(25):2391&#x2013;402. doi:&#xa0;10.1056/NEJMoa1910962\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31562799/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1910962\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Gonz%C3%A1lez-Mart%C3%ADn&amp;author=B+Pothuri&amp;author=I+Vergote&amp;author=R+DePont%20Christensen&amp;author=W+Graybill&amp;author=MR+Mirza&amp;publication_year=2019&amp;title=Niraparib%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer&amp;journal=New+Engl+J+Med&amp;volume=381&amp;pages=2391-402\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic epidemiology of breast cancer in Latin America. \u003Ci>Genes (Basel)\u003C/i> (2019) 10(2). doi: 10.3390/genes10020153\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30781715/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/genes10020153\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=VA+Zavala&amp;author=SJ+Serrano-Gomez&amp;author=J+Dutil&amp;author=L+Fejerman&amp;publication_year=2019&amp;title=Genetic%20epidemiology%20of%20breast%20cancer%20in%20Latin%20America&amp;journal=Genes+(Basel)&amp;volume=10&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Ossa CA, Torres D. Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries: state of the art and literature review. \u003Ci>Oncologist\u003C/i> (2016) 21(7):832&#x2013;9. doi: 10.1634/theoncologist.2015-0416\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27286788/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1634/theoncologist.2015-0416\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CA+Ossa&amp;author=D+Torres&amp;publication_year=2016&amp;title=Founder%20and%20recurrent%20mutations%20in%20BRCA1%20and%20BRCA2%20genes%20in%20Latin%20American%20countries%3A%20state%20of%20the%20art%20and%20literature%20review&amp;journal=Oncologist&amp;volume=21&amp;pages=832-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Buleje J, Guevara-Fujita M, Acosta O, Huaman FDP, Danos P, Murillo A, et al. Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. \u003Ci>Mol Genet Genomic Med\u003C/i> (2017) 5(5). doi: 10.1002/mgg3.301\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28944232/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/mgg3.301\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Buleje&amp;author=M+Guevara-Fujita&amp;author=O+Acosta&amp;author=FDP+Huaman&amp;author=P+Danos&amp;author=A+Murillo&amp;publication_year=2017&amp;title=Mutational%20analysis%20of%20BRCA1%20and%20BRCA2%20genes%20in%20Peruvian%20families%20with%20hereditary%20breast%20and%20ovarian%20cancer&amp;journal=Mol+Genet+Genomic+Med&amp;volume=5&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, et al. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. \u003Ci>Aging\u003C/i> (2021) 13(6):8975&#x2013;88. doi: 10.18632/aging.202724\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33705352/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/aging.202724\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Shao&amp;author=Y+Duan&amp;author=Y+Zhao&amp;author=Y+Li&amp;author=J+Liu&amp;author=C+Zhang&amp;publication_year=2021&amp;title=PARP%20inhibitors%20in%20breast%20and%20ovarian%20cancer%20with%20BRCA%20mutations%3A%20a%20meta-analysis%20of%20survival&amp;journal=Aging&amp;volume=13&amp;pages=8975-88\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Pinto JA, Pinillos L, Villarreal-Garza C, Morante Z, Villar&#xe1;n MV, Mej&#xed;a G, et al. Barriers in Latin America for the management of locally advanced breast cancer. \u003Ci>Ecancermedicalscience\u003C/i> (2019) 13. doi: 10.3332/ecancer.2019.897\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3332/ecancer.2019.897\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JA+Pinto&amp;author=L+Pinillos&amp;author=C+Villarreal-Garza&amp;author=Z+Morante&amp;author=MV+Villar%C3%A1n&amp;author=G+Mej%C3%ADa&amp;publication_year=2019&amp;title=Barriers%20in%20Latin%20America%20for%20the%20management%20of%20locally%20advanced%20breast%20cancer&amp;journal=Ecancermedicalscience&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Horgan D, Mia R, Erhabor T, Hamdi Y, Dandara C, Lal JA, et al. Fighting cancer around the world: A framework for action. \u003Ci>Healthc (Basel)\u003C/i> (2022) 10(11). doi: 10.3390/healthcare10112125\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/healthcare10112125\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Horgan&amp;author=R+Mia&amp;author=T+Erhabor&amp;author=Y+Hamdi&amp;author=C+Dandara&amp;author=JA+Lal&amp;publication_year=2022&amp;title=Fighting%20cancer%20around%20the%20world%3A%20A%20framework%20for%20action&amp;journal=Healthc+(Basel)&amp;volume=10&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. \u003Ci>Hum Mutat\u003C/i> (2018) 39(5):593&#x2013;620. doi: 10.1002/humu.23406\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29446198/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23406\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=TM+Friebel&amp;author=E+Friedman&amp;author=U+Hamann&amp;author=D+Huo&amp;author=A+Kwong&amp;publication_year=2018&amp;title=Mutational%20spectrum%20in%20a%20worldwide%20study%20of%2029%2C700%20families%20with%20BRCA1%20or%20BRCA2%20mutations&amp;journal=Hum+Mutat&amp;volume=39&amp;pages=593\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Hartwig M, Janiszewska H, Bak A, Pilarska M, Heise M, Junkiert-Czarnecka A, et al. Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country. \u003Ci>Contemp Oncol (Pozn)\u003C/i> (2013) 17(1):34&#x2013;7. doi:&#xa0;10.5114/wo.2013.33767\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23788959/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.5114/wo.2013.33767\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Hartwig&amp;author=H+Janiszewska&amp;author=A+Bak&amp;author=M+Pilarska&amp;author=M+Heise&amp;author=A+Junkiert-Czarnecka&amp;publication_year=2013&amp;title=Prevalence%20of%20the%20BRCA1%20c.68_69delAG%20%28BIC%3A%20185delAG%29%20mutation%20in%20women%20with%20breast%20cancer%20from%20north-central%20Poland%20and%20a%20review%20of%20the%20literature%20on%20other%20regions%20of%20the%20country&amp;journal=Contemp+Oncol+(Pozn)&amp;volume=17&amp;pages=34-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, et al. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. \u003Ci>Eur J Hum Genet\u003C/i> (2013) 21(2):212&#x2013;6. doi: 10.1038/ejhg.2012.124\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22763381/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ejhg.2012.124\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Laitman&amp;author=BJ+Feng&amp;author=IM+Zamir&amp;author=JN+Weitzel&amp;author=P+Duncan&amp;author=D+Port&amp;publication_year=2013&amp;title=Haplotype%20analysis%20of%20the%20185delAG%20BRCA1%20mutation%20in%20ethnically%20diverse%20populations&amp;journal=Eur+J+Hum+Genet&amp;volume=21&amp;pages=212-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Villarreal-Garza C, Alvarez-G&#xf3;mez RM, P&#xe9;rez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. \u003Ci>Cancer\u003C/i> (2015) 121(3):372&#x2013;8. doi: 10.1002/cncr.29058\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25236687/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.29058\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Villarreal-Garza&amp;author=RM+Alvarez-G%C3%B3mez&amp;author=C+P%C3%A9rez-Plasencia&amp;author=LA+Herrera&amp;author=J+Herzog&amp;author=D+Castillo&amp;publication_year=2015&amp;title=Significant%20clinical%20impact%20of%20recurrent%20BRCA1%20and%20BRCA2%20mutations%20in%20Mexico&amp;journal=Cancer&amp;volume=121&amp;pages=372-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. \u003Ci>Fam Cancer\u003C/i> (2018) 17(1):23&#x2013;30. doi: 10.1007/s10689-017-0004-z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28528518/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10689-017-0004-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AM+Cock-Rada&amp;author=CA+Ossa&amp;author=HI+Garcia&amp;author=LR+Gomez&amp;publication_year=2018&amp;title=A%20multi-gene%20panel%20study%20in%20hereditary%20breast%20and%20ovarian%20cancer%20in%20Colombia&amp;journal=Fam+Cancer&amp;volume=17&amp;pages=23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, et al. Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. \u003Ci>Genet Mol Biol\u003C/i> (2012) 35(3):599&#x2013;602. doi: 10.1590/S1415-47572012000400009\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23055798/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1590/S1415-47572012000400009\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CV+Dillenburg&amp;author=IC+Bandeira&amp;author=TV+Tubino&amp;author=LG+Rossato&amp;author=ES+Dias&amp;author=AC+Bittelbrunn&amp;publication_year=2012&amp;title=Prevalence%20of%20185delAG%20and%205382insC%20mutations%20in%20BRCA1%2C%20and%206174delT%20in%20BRCA2%20in%20women%20of%20Ashkenazi%20Jewish%20origin%20in%20southern%20Brazil&amp;journal=Genet+Mol+Biol&amp;volume=35&amp;pages=599\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Abugattas J, Llacuachaqui M, Allende YS, Vel&#xe1;squez AA, Velarde R, Cotrina J, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. \u003Ci>Clin Genet\u003C/i> (2015) 88(4):371&#x2013;5. doi: 10.1111/cge.12505\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25256238/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12505\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Abugattas&amp;author=M+Llacuachaqui&amp;author=YS+Allende&amp;author=AA+Vel%C3%A1squez&amp;author=R+Velarde&amp;author=J+Cotrina&amp;publication_year=2015&amp;title=Prevalence%20of%20BRCA1%20and%20BRCA2%20mutations%20in%20unselected%20breast%20cancer%20patients%20from%20Peru&amp;journal=Clin+Genet&amp;volume=88&amp;pages=371-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. \u003Ci>Hered Cancer Clin Pract\u003C/i> (2018) 16(1):1&#x2013;15. doi:&#xa0;10.1186/s13053-017-0085-6\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29308099/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13053-017-0085-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Heramb&amp;author=T+Wangensteen&amp;author=EM+Grindedal&amp;author=SL+Ariansen&amp;author=S+Lothe&amp;author=KR+Heimdal&amp;publication_year=2018&amp;title=BRCA1%20and%20BRCA2%20mutation%20spectrum%20-%20an%20update%20on%20mutation%20distribution%20in%20a%20large%20cancer%20genetics%20clinic%20in%20Norway&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=16&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Scheuner MT, McNeel TS, Freedman AN. Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey. \u003Ci>Genet Med\u003C/i> (2010) 12(11):726&#x2013;35. doi:&#xa0;10.1097/GIM.0b013e3181f30e9e\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20921897/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/GIM.0b013e3181f30e9e\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MT+Scheuner&amp;author=TS+McNeel&amp;author=AN+Freedman&amp;publication_year=2010&amp;title=Population%20prevalence%20of%20familial%20cancer%20and%20common%20hereditary%20cancer%20syndromes.%20The%202005%20California%20Health%20Interview%20Survey&amp;journal=Genet+Med&amp;volume=12&amp;pages=726-35\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Ndiaye R, Diop JPD, Bourdon-Huguenin V, Dem A, Diouf D, Dieng MM, et al. Evidence for an ancient BRCA 1 pathogenic variant in inherited breast cancer patients from Senegal. \u003Ci>NPJ Genom Med\u003C/i> (2020) 5(1). doi: 10.1038/s41525-020-0114-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32025337/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41525-020-0114-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Ndiaye&amp;author=JPD+Diop&amp;author=V+Bourdon-Huguenin&amp;author=A+Dem&amp;author=D+Diouf&amp;author=MM+Dieng&amp;publication_year=2020&amp;title=Evidence%20for%20an%20ancient%20BRCA%201%20pathogenic%20variant%20in%20inherited%20breast%20cancer%20patients%20from%20Senegal&amp;journal=NPJ+Genom+Med&amp;volume=5&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Vargas E, Torres Lopez DM, Deugd R, Gil F, Nova A, Mora L, et al. Low prevalence of the four common Colombian founder mutations in BRCA1 and BRCA2 in early-onset and familial afro-Colombian patients with breast cancer. \u003Ci>Oncologist\u003C/i> (2019) 24(7):e475&#x2013;9. doi: 10.1634/theoncologist.2018-0346\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30541753/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1634/theoncologist.2018-0346\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Vargas&amp;author=DM+Torres%20Lopez&amp;author=R+Deugd&amp;author=F+Gil&amp;author=A+Nova&amp;author=L+Mora&amp;publication_year=2019&amp;title=Low%20prevalence%20of%20the%20four%20common%20Colombian%20founder%20mutations%20in%20BRCA1%20and%20BRCA2%20in%20early-onset%20and%20familial%20afro-Colombian%20patients%20with%20breast%20cancer&amp;journal=Oncologist&amp;volume=24&amp;pages=e475-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> 33. Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, et al. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. \u003Ci>NPJ Breast Cancer\u003C/i> (2021) 7(1). doi: 10.1038/s41523-021-00317-6\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34413315/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41523-021-00317-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JS+Herzog&amp;author=Y+Chavarri-Guerra&amp;author=D+Castillo&amp;author=J+Abugattas&amp;author=C+Villarreal-Garza&amp;author=S+Sand&amp;publication_year=2021&amp;title=Genetic%20epidemiology%20of%20BRCA1-%20and%20BRCA2-associated%20cancer%20across%20Latin%20America&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> 34. Molina J, Fernandez OOC, Lim M, Mas L, Veliz IF, Vargas C. BRCA 1/2 mutations in high-grade serous ovarian cancer (HGS-OC) patients of three Latin American countries: Report of 412 cases. \u003Ci>J Clin Oncol\u003C/i> (2019) 37(15_suppl):e14288&#x2013;8. doi: 10.1200/JCO.2019.37.15_suppl.e14288\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1200/JCO.2019.37.15_suppl.e14288\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Molina&amp;author=OOC+Fernandez&amp;author=M+Lim&amp;author=L+Mas&amp;author=IF+Veliz&amp;author=C+Vargas&amp;publication_year=2019&amp;title=BRCA%201%2F2%20mutations%20in%20high-grade%20serous%20ovarian%20cancer%20%28HGS-OC%29%20patients%20of%20three%20Latin%20American%20countries%3A%20Report%20of%20412%20cases&amp;journal=J+Clin+Oncol&amp;volume=37&amp;pages=e14288-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> 35. Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. \u003Ci>Biol Res\u003C/i> (2017) 50(1). doi: 10.1186/s40659-017-0139-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28985766/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s40659-017-0139-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Jara&amp;author=S+Morales&amp;author=T+de%20Mayo&amp;author=P+Gonzalez-Hormazabal&amp;author=V+Carrasco&amp;author=R+Godoy&amp;publication_year=2017&amp;title=Mutations%20in%20BRCA1%2C%20BRCA2%20and%20other%20breast%20and%20ovarian%20cancer%20susceptibility%20genes%20in%20Central%20and%20South%20American%20populations&amp;journal=Biol+Res&amp;volume=50&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> 36. Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Guti&#xe9;rrez LG. Study of the genetic variants in BRCA1/2 and non- BRCA genes in a population-based cohort of 2155 breast/ovary cancer patients, including 443 triple-negative breast cancer patients, in Argentina. \u003Ci>Cancers (Basel)\u003C/i> (2021) 13(11). doi: 10.3390/cancers13112711\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34072659/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/cancers13112711\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AR+Solano&amp;author=PG+Mele&amp;author=FS+Jalil&amp;author=NC+Liria&amp;author=EJ+Podesta&amp;author=LG+Guti%C3%A9rrez&amp;publication_year=2021&amp;title=Study%20of%20the%20genetic%20variants%20in%20BRCA1%2F2%20and%20non-%20BRCA%20genes%20in%20a%20population-based%20cohort%20of%202155%20breast%2Fovary%20cancer%20patients%2C%20including%20443%20triple-negative%20breast%20cancer%20patients%2C%20in%20Argentina&amp;journal=Cancers+(Basel)&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> 37. Bhaskaran SP, Huang T, Rajendran BK, Guo M, Luo J, Qin Z, et al. Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations. \u003Ci>J Med Genet\u003C/i> (2021) 58(11):752&#x2013;9. doi: 10.1136/jmedgenet-2020-107299\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32963034/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmedgenet-2020-107299\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SP+Bhaskaran&amp;author=T+Huang&amp;author=BK+Rajendran&amp;author=M+Guo&amp;author=J+Luo&amp;author=Z+Qin&amp;publication_year=2021&amp;title=Ethnic-specific%20BRCA1%2F2%20variation%20within%20Asia%20population%3A%20evidence%20from%20over%2078%20000%20cancer%20and%2040%20000%20non-cancer%20cases%20of%20Indian%2C%20Chinese%2C%20Korean%20and%20Japanese%20populations&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=752-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> 38. Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubi&#x144;ski J, et al. Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. \u003Ci>Hered Cancer Clin Pract\u003C/i> (2018) 16(1). doi: 10.1186/s13053-018-0089-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29492181/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13053-018-0089-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Kluz&amp;author=A+Jasiewicz&amp;author=E+Marczyk&amp;author=R+Jach&amp;author=A+Jakubowska&amp;author=J+Lubi%C5%84ski&amp;publication_year=2018&amp;title=Frequency%20of%20BRCA1%20and%20BRCA2%20causative%20founder%20variants%20in%20ovarian%20cancer%20patients%20in%20South-East%20Poland&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=16&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> 39. Kechin A, Boyarskikh U, Barinov A, Tanas A, Kazakova S, Zhevlova A, et al. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. \u003Ci>Breast Cancer Res Treat\u003C/i> (2023) 197(2):387&#x2013;95. doi: 10.1007/s10549-022-06782-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/36367610/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-022-06782-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Kechin&amp;author=U+Boyarskikh&amp;author=A+Barinov&amp;author=A+Tanas&amp;author=S+Kazakova&amp;author=A+Zhevlova&amp;publication_year=2023&amp;title=A%20spectrum%20of%20BRCA1%20and%20BRCA2%20germline%20deleterious%20variants%20in%20ovarian%20cancer%20in%20Russia&amp;journal=Breast+Cancer+Res+Treat&amp;volume=197&amp;pages=387-95\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> 40. Gabald&#xf3; Barrios X, Sarabia Meseguer MD, Mar&#xed;n Vera M, S&#xe1;nchez Berm&#xfa;dez AI, Mac&#xed;as Cerrolaza JA, S&#xe1;nchez Henarejos P, et al. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. \u003Ci>Fam Cancer\u003C/i> (2017) 16(4):477&#x2013;89. doi: 10.1007/s10689-017-9985-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28477318/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10689-017-9985-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X+Gabald%C3%B3%20Barrios&amp;author=MD+Sarabia%20Meseguer&amp;author=M+Mar%C3%ADn%20Vera&amp;author=AI+S%C3%A1nchez%20Berm%C3%BAdez&amp;author=JA+Mac%C3%ADas%20Cerrolaza&amp;author=P+S%C3%A1nchez%20Henarejos&amp;publication_year=2017&amp;title=Molecular%20characterization%20and%20clinical%20interpretation%20of%20BRCA1%2FBRCA2%20variants%20in%20families%20from%20Murcia%20%28south-eastern%20Spain%29%20with%20hereditary%20breast%20and%20ovarian%20cancer%3A%20clinical-pathological%20features%20in%20BRCA%20carriers%20and%20non-carriers&amp;journal=Fam+Cancer&amp;volume=16&amp;pages=477-89\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> 41. Nguyen-Dumont T, Karpinski P, Sasiadek MM, Akopyan H, Steen JA, Theys D, et al. Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer? \u003Ci>Genet Res (Camb)\u003C/i> (2020) 102. doi: 10.1017/S0016672320000075\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32772980/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1017/S0016672320000075\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Nguyen-Dumont&amp;author=P+Karpinski&amp;author=MM+Sasiadek&amp;author=H+Akopyan&amp;author=JA+Steen&amp;author=D+Theys&amp;publication_year=2020&amp;title=Genetic%20testing%20in%20Poland%20and%20Ukraine%3A%20should%20comprehensive%20germline%20testing%20of%20BRCA1%20and%20BRCA2%20be%20recommended%20for%20women%20with%20breast%20and%20ovarian%20cancer&amp;journal=Genet+Res+(Camb)&amp;volume=102&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> 42. Manzanares Campillo M, Mu&#xf1;oz Atienza V, S&#xe1;nchez Tapia EM, Mart&#xed;n Fern&#xe1;ndez J. Portadoras de mutaciones en BRCA1 y 2 en familias de alto riesgo del &#xe1;rea de Ciudad Real (Espa&#xf1;a): prevalencia mutacional y caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas del c&#xe1;ncer de mama y ovario. \u003Ci>Rev Senol Y Patol Mamaria  J Breast Sci\u003C/i> (2018) 31(2):59&#x2013;66. doi:&#xa0;10.1016/j.senol.2018.04.002\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1016/j.senol.2018.04.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Manzanares%20Campillo&amp;author=V+Mu%C3%B1oz%20Atienza&amp;author=EM+S%C3%A1nchez%20Tapia&amp;author=J+Mart%C3%ADn%20Fern%C3%A1ndez&amp;publication_year=2018&amp;title=Portadoras%20de%20mutaciones%20en%20BRCA1%20y%202%20en%20familias%20de%20alto%20riesgo%20del%20%C3%A1rea%20de%20Ciudad%20Real%20%28Espa%C3%B1a%29%3A%20prevalencia%20mutacional%20y%20caracter%C3%ADsticas%20cl%C3%ADnico-patol%C3%B3gicas%20del%20c%C3%A1ncer%20de%20mama%20y%20ovario&amp;journal=Rev+Senol+Y+Patol+Mamaria++J+Breast+Sci&amp;volume=31&amp;pages=59\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> 43. Kang PCE, Phuah SY, Sivanandan K, Kang IN, Thirthagiri E, Liu JJ, et al. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history. \u003Ci>Breast Cancer Res Treat\u003C/i> (2014) 144(3):635&#x2013;42. doi: 10.1007/s10549-014-2894-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24578176/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-014-2894-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PCE+Kang&amp;author=SY+Phuah&amp;author=K+Sivanandan&amp;author=IN+Kang&amp;author=E+Thirthagiri&amp;author=JJ+Liu&amp;publication_year=2014&amp;title=Recurrent%20mutation%20testing%20of%20BRCA1%20and%20BRCA2%20in%20Asian%20breast%20cancer%20patients%20identify%20carriers%20in%20those%20with%20presumed%20low%20risk%20by%20family%20history&amp;journal=Breast+Cancer+Res+Treat&amp;volume=144&amp;pages=635-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> 44. Gallardo-Rinc&#xf3;n D, Montes-Serv&#xed;n E, Alamilla-Garc&#xed;a G, Montes-Serv&#xed;n E, Bahena-Gonz&#xe1;lez A, Cetina-P&#xe9;rez L, et al. Clinical benefits of olaparib in mexican ovarian cancer patients with founder mutation BRCA1-del ex9-12. \u003Ci>Front Genet\u003C/i> (2022) 13. doi:&#xa0;10.3389/fgene.2022.863956\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35734436/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2022.863956\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Gallardo-Rinc%C3%B3n&amp;author=E+Montes-Serv%C3%ADn&amp;author=G+Alamilla-Garc%C3%ADa&amp;author=E+Montes-Serv%C3%ADn&amp;author=A+Bahena-Gonz%C3%A1lez&amp;author=L+Cetina-P%C3%A9rez&amp;publication_year=2022&amp;title=Clinical%20benefits%20of%20olaparib%20in%20mexican%20ovarian%20cancer%20patients%20with%20founder%20mutation%20BRCA1-del%20ex9-12&amp;journal=Front+Genet&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> 45. Fernandes GC, Michelli RAD, Galv&#xe3;o HCR, Paula AE, Pereira R, Andrade CE, et al. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. \u003Ci>Oncotarget\u003C/i> (2016) 7(49):80465&#x2013;81. doi: 10.18632/oncotarget.12610\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27741520/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/oncotarget.12610\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=GC+Fernandes&amp;author=RAD+Michelli&amp;author=HCR+Galv%C3%A3o&amp;author=AE+Paula&amp;author=R+Pereira&amp;author=CE+Andrade&amp;publication_year=2016&amp;title=Prevalence%20of%20BRCA1%2FBRCA2%20mutations%20in%20a%20Brazilian%20population%20sample%20at-risk%20for%20hereditary%20breast%20cancer%20and%20characterization%20of%20its%20genetic%20ancestry&amp;journal=Oncotarget&amp;volume=7&amp;pages=80465-81\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> 46. Jarhelle E, Riise Stensland HMF, M&#xe6;hle L, Van Ghelue M. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort. \u003Ci>Fam Cancer\u003C/i> (2017) 16(1):1&#x2013;16. doi: 10.1007/s10689-016-9916-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27495310/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10689-016-9916-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Jarhelle&amp;author=HMF+Riise%20Stensland&amp;author=L+M%C3%A6hle&amp;author=M+Van%20Ghelue&amp;publication_year=2017&amp;title=Characterization%20of%20BRCA1%20and%20BRCA2%20variants%20found%20in%20a%20Norwegian%20breast%20or%20ovarian%20cancer%20cohort&amp;journal=Fam+Cancer&amp;volume=16&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a> 47. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadal&#xf3; L, et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. \u003Ci>Hum Mutat\u003C/i> (2019) 40(9):1557&#x2013;78. doi:&#xa0;10.1002/humu.23818\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31131967/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23818\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MT+Parsons&amp;author=E+Tudini&amp;author=H+Li&amp;author=E+Hahnen&amp;author=B+Wappenschmidt&amp;author=L+Feliubadal%C3%B3&amp;publication_year=2019&amp;title=Large%20scale%20multifactorial%20likelihood%20quantitative%20analysis%20of%20BRCA1%20and%20BRCA2%20variants%3A%20An%20ENIGMA%20resource%20to%20support%20clinical%20variant%20classification&amp;journal=Hum+Mutat&amp;volume=40&amp;pages=1557-78\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a> 48. Ponce J, Vigil C, Araujo J, Casta&#xf1;eda C, Calderon G, Buleje J, et al. Abstract P5-09-08: Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1. \u003Ci>Cancer Res\u003C/i> (2017) 77(4_Supplement):P5-09-08. doi:&#xa0;10.1158/1538-7445.SABCS16-P5-09-08\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1158/1538-7445.SABCS16-P5-09-08\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Ponce&amp;author=C+Vigil&amp;author=J+Araujo&amp;author=C+Casta%C3%B1eda&amp;author=G+Calderon&amp;author=J+Buleje&amp;publication_year=2017&amp;title=Abstract%20P5-09-08%3A%20Molecular%20evaluation%20of%20Peruvian%20patients%20with%20hereditary%20breast%20cancer%20reveals%20a%20novel%20germline%20mutation%20in%20BRCA1&amp;journal=Cancer+Res&amp;volume=77&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a> 49. Pal T, Bonner D, Cragun D, Monteiro ANA, Phelan C, Servais L, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. \u003Ci>Cancer\u003C/i> (2015) 121(23):4173&#x2013;80. doi: 10.1002/cncr.29645\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26287763/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.29645\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Pal&amp;author=D+Bonner&amp;author=D+Cragun&amp;author=ANA+Monteiro&amp;author=C+Phelan&amp;author=L+Servais&amp;publication_year=2015&amp;title=A%20high%20frequency%20of%20BRCA%20mutations%20in%20young%20black%20women%20with%20breast%20cancer%20residing%20in%20Florida&amp;journal=Cancer&amp;volume=121&amp;pages=4173-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a> 50. D&#xed;ez O, Osorio A, Dur&#xe1;n M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. \u003Ci>Hum Mutat\u003C/i> (2003) 22(4):301&#x2013;12. doi: 10.1002/humu.10260\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12955716/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.10260\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O+D%C3%ADez&amp;author=A+Osorio&amp;author=M+Dur%C3%A1n&amp;author=JI+Martinez-Ferrandis&amp;author=M+de%20la%20Hoya&amp;author=R+Salazar&amp;publication_year=2003&amp;title=Analysis%20of%20BRCA1%20and%20BRCA2%20genes%20in%20Spanish%20breast%2Fovarian%20cancer%20patients%3A%20a%20high%20proportion%20of%20mutations%20unique%20to%20Spain%20and%20evidence%20of%20founder%20effects&amp;journal=Hum+Mutat&amp;volume=22&amp;pages=301-12\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a> 51. Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, et al. Non-founder BRCA1 mutations in Russian breast cancer patients. \u003Ci>Cancer Lett\u003C/i> (2010) 298(2):258&#x2013;63. doi: 10.1016/j.canlet.2010.07.013\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20727672/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.canlet.2010.07.013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AG+Iyevleva&amp;author=EN+Suspitsin&amp;author=K+Kroeze&amp;author=TV+Gorodnova&amp;author=AP+Sokolenko&amp;author=KG+Buslov&amp;publication_year=2010&amp;title=Non-founder%20BRCA1%20mutations%20in%20Russian%20breast%20cancer%20patients&amp;journal=Cancer+Lett&amp;volume=298&amp;pages=258-63\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a> 52. Vidal AF, Ferraz RS, El-Husny A, Silva CS, Vinasco-Sandoval T, Magalh&#xe3;es L, et al. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation. \u003Ci>BMC Cancer\u003C/i> (2021) 21(1). doi: 10.1186/s12885-021-08089-9\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33827469/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12885-021-08089-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AF+Vidal&amp;author=RS+Ferraz&amp;author=A+El-Husny&amp;author=CS+Silva&amp;author=T+Vinasco-Sandoval&amp;author=L+Magalh%C3%A3es&amp;publication_year=2021&amp;title=Comprehensive%20analysis%20of%20germline%20mutations%20in%20northern%20Brazil%3A%20a%20panel%20of%2016%20genes%20for%20hereditary%20cancer-predisposing%20syndrome%20investigation&amp;journal=BMC+Cancer&amp;volume=21&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a> 53. Rogo&#x17c;a-Janiszewska E, Mali&#x144;ska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, et al. Prevalence of recurrent mutations predisposing to breast cancer in early-onset breast cancer patients from Poland. \u003Ci>Cancers (Basel)\u003C/i> (2020) 12(8):1&#x2013;10. doi:&#xa0;10.3390/cancers12082321\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/cancers12082321\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Rogo%C5%BCa-Janiszewska&amp;author=K+Mali%C5%84ska&amp;author=C+Cybulski&amp;author=A+Jakubowska&amp;author=J+Gronwald&amp;author=T+Huzarski&amp;publication_year=2020&amp;title=Prevalence%20of%20recurrent%20mutations%20predisposing%20to%20breast%20cancer%20in%20early-onset%20breast%20cancer%20patients%20from%20Poland&amp;journal=Cancers+(Basel)&amp;volume=12&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a> 54. Szwiec M, Jakubowska A, G&#xf3;rski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. \u003Ci>Clin Genet\u003C/i> (2015) 87(3):288&#x2013;92. doi: 10.1111/cge.12360\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24528374/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12360\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Szwiec&amp;author=A+Jakubowska&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=J+Tomiczek-Szwiec&amp;author=J+Gronwald&amp;publication_year=2015&amp;title=Recurrent%20mutations%20of%20BRCA1%20and%20BRCA2%20in%20Poland%3A%20an%20update&amp;journal=Clin+Genet&amp;volume=87&amp;pages=288-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a> 55. Blay P, Santamar&#xed;a I, Pitiot AS, Luque M, Alvarado MG, Lastra A, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). \u003Ci>BMC Cancer\u003C/i> (2013) 13. doi: 10.1186/1471-2407-13-243\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23683081/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1471-2407-13-243\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Blay&amp;author=I+Santamar%C3%ADa&amp;author=AS+Pitiot&amp;author=M+Luque&amp;author=MG+Alvarado&amp;author=A+Lastra&amp;publication_year=2013&amp;title=Mutational%20analysis%20of%20BRCA1%20and%20BRCA2%20in%20hereditary%20breast%20and%20ovarian%20cancer%20families%20from%20Asturias%20%28Northern%20Spain%29&amp;journal=BMC+Cancer&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a> 56. Kim JH, Park S, Park HS, Park JS, Lee ST, Kim SW, et al. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study. \u003Ci>Sci Rep\u003C/i> (2021) 11(1). doi: 10.1038/s41598-021-87792-w\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41598-021-87792-w\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JH+Kim&amp;author=S+Park&amp;author=HS+Park&amp;author=JS+Park&amp;author=ST+Lee&amp;author=SW+Kim&amp;publication_year=2021&amp;title=Analysis%20of%20BRCA1%2F2%20variants%20of%20unknown%20significance%20in%20the%20prospective%20Korean%20Hereditary%20Breast%20Cancer%20study&amp;journal=Sci+Rep&amp;volume=11&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a> 57. Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, et al. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. \u003Ci>Cancer\u003C/i> (2016) 122(1):84&#x2013;90. doi: 10.1002/cncr.29707\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26439132/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.29707\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Sakamoto&amp;author=Y+Hirotsu&amp;author=H+Nakagomi&amp;author=H+Ouchi&amp;author=A+Ikegami&amp;author=K+Teramoto&amp;publication_year=2016&amp;title=BRCA1%20and%20BRCA2%20mutations%20in%20Japanese%20patients%20with%20ovarian%2C%20fallopian%20tube%2C%20and%20primary%20peritoneal%20cancer&amp;journal=Cancer&amp;volume=122&amp;pages=84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a> 58. Yamaguchi-Kabata Y, Yasuda J, Tanabe O, Suzuki Y, Kawame H, Fuse N, et al. Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. \u003Ci>J Hum Genet\u003C/i> (2017) 63(2):213&#x2013;30. doi:&#xa0;10.1038/s10038-017-0347-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29192238/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s10038-017-0347-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Yamaguchi-Kabata&amp;author=J+Yasuda&amp;author=O+Tanabe&amp;author=Y+Suzuki&amp;author=H+Kawame&amp;author=N+Fuse&amp;publication_year=2017&amp;title=Evaluation%20of%20reported%20pathogenic%20variants%20and%20their%20frequencies%20in%20a%20Japanese%20population%20based%20on%20a%20whole-genome%20reference%20panel%20of%202049%20individuals&amp;journal=J+Hum+Genet&amp;volume=63&amp;pages=213-30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a> 59. Tokunaga H, Iida K, Hozawa A, Ogishima S, Watanabe Y, Shigeta S, et al. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). \u003Ci>PloS One\u003C/i> (2021) 16(1). doi: 10.1371/journal.pone.0236907\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1371/journal.pone.0236907\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Tokunaga&amp;author=K+Iida&amp;author=A+Hozawa&amp;author=S+Ogishima&amp;author=Y+Watanabe&amp;author=S+Shigeta&amp;publication_year=2021&amp;title=Novel%20candidates%20of%20pathogenic%20variants%20of%20the%20BRCA1%20and%20BRCA2%20genes%20from%20a%20dataset%20of%203%2C552%20Japanese%20whole%20genomes%20%283.5KJPNv2%29&amp;journal=PloS+One&amp;volume=16&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a> 60. Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. \u003Ci>Mol Genet Genomic Med\u003C/i> (2015) 3(2):121&#x2013;9. doi: 10.1002/mgg3.120\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25802882/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/mgg3.120\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Hirotsu&amp;author=H+Nakagomi&amp;author=I+Sakamoto&amp;author=K+Amemiya&amp;author=H+Mochizuki&amp;author=M+Omata&amp;publication_year=2015&amp;title=Detection%20of%20BRCA1%20and%20BRCA2%20germline%20mutations%20in%20Japanese%20population%20using%20next-generation%20sequencing&amp;journal=Mol+Genet+Genomic+Med&amp;volume=3&amp;pages=121-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a> 61. Torres-Mej&#xed;a G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Mart&#xed;nez-Matsushita L, et al. Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. \u003Ci>Cancer Epidemiol Biomarkers Prev\u003C/i> (2015) 24(3):498&#x2013;505. doi: 10.1158/1055-9965.EPI-13-0980\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25371446/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.EPI-13-0980\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Torres-Mej%C3%ADa&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=MR+Akbari&amp;author=AR+Giuliano&amp;author=L+Mart%C3%ADnez-Matsushita&amp;publication_year=2015&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20mutations%20in%20Mexican%20women%20with%20breast%20cancer&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=24&amp;pages=498\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> breast cancer, ovarian cancer, BRCA1, BRCA2, germline mutation\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Ferreyra Y, Rosas G, Cock-Rada AM, Araujo J, Bravo L, Doimi F, Casas J, Clavo Mdl&#xc1;, Pinto JA and Belmar-L&#xf3;pez C (2023) Landscape of germline \u003Ci>BRCA1/BRCA2\u003C/i> variants in breast and ovarian cancer in Peru. \u003Ci>Front. Oncol.\u003C/i> 13:1227864. doi: 10.3389/fonc.2023.1227864\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 23 May 2023; \u003Cspan>Accepted:\u003C/span> 27 July 2023;\u003Cbr>\u003Cspan>Published:\u003C/span> 17 August 2023.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/2020199\">Charles Theillet\u003C/a>, Institut du Cancer de Montpellier (ICM), France\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/2333558\">Ekaterina Kuligina\u003C/a>, N.N. Petrov National Medical Research Center of Oncology, Russia\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/558253\">Alvaro Galli\u003C/a>, National Research Council (CNR), Italy\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#xa9; 2023 Ferreyra, Rosas, Cock-Rada, Araujo, Bravo, Doimi, Casas, Clavo, Pinto and Belmar-L&#xf3;pez. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Joseph A. Pinto, \u003Ca id=\"encmail\">anBpbnRvQGdlY29wZXJ1Lm9yZw==\u003C/a>\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Background\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Data availability statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Ethics statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Author contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Conflict of interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Publisher&#x2019;s note\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Supplementary material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">Abbreviations\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">References\u003C/a>\u003C/li>\u003C/ul>",[685,690,695,698,703],{"name":686,"fileServerPackageEntryId":19,"fileServerId":687,"fileServerVersionNumber":669,"type":688},"EPUB.epub","1227864/epub",{"code":689,"name":689},"EPUB",{"name":691,"fileServerPackageEntryId":691,"fileServerId":692,"fileServerVersionNumber":669,"type":693},"fonc-13-1227864.pdf","1227864/pubmed-zip",{"code":694,"name":694},"PDF",{"name":691,"fileServerPackageEntryId":19,"fileServerId":696,"fileServerVersionNumber":669,"type":697},"1227864/publishers-proof/pdf",{"code":694,"name":694},{"name":699,"fileServerPackageEntryId":699,"fileServerId":692,"fileServerVersionNumber":669,"type":700},"fonc-13-1227864.xml",{"code":701,"name":702},"NLM_XML","XML",{"name":704,"fileServerPackageEntryId":19,"fileServerId":705,"fileServerVersionNumber":391,"type":706},"Provisional PDF.pdf","1227864/provisional-pdf",{"code":694,"name":694},"v3",{"title":709,"link":710,"meta":714,"script":848},"Frontiers | Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru",[711],{"rel":712,"href":713},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/full",[715,718,721,723,726,730,733,737,740,743,746,748,750,752,754,756,759,762,764,767,769,771,774,777,780,783,786,790,794,797,800,803,806,809,812,815,818,821,824,827,829,832,835,838,840,843,845],{"hid":716,"property":716,"name":716,"content":717},"description","There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conduc...",{"hid":719,"property":719,"name":720,"content":709},"og:title","title",{"hid":722,"property":722,"name":716,"content":717},"og:description",{"hid":724,"name":724,"content":725},"keywords","breast cancer,ovarian cancer,BRCA1,BRCA2,germline mutation",{"hid":727,"property":727,"name":728,"content":729},"og:site_name","site_name","Frontiers",{"hid":731,"property":731,"name":384,"content":732},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1227864/fonc-13-1227864-HTML-r1/image_m/fonc-13-1227864-g001.jpg",{"hid":734,"property":734,"name":735,"content":736},"og:type","type","article",{"hid":738,"property":738,"name":739,"content":713},"og:url","url",{"hid":741,"name":741,"content":742},"twitter:card","summary_large_image",{"hid":744,"name":744,"content":745},"citation_volume","13",{"hid":747,"name":747,"content":116},"citation_journal_title",{"hid":749,"name":749,"content":729},"citation_publisher",{"hid":751,"name":751,"content":665},"citation_journal_abbrev",{"hid":753,"name":753,"content":666},"citation_issn",{"hid":755,"name":755,"content":536},"citation_doi",{"hid":757,"name":757,"content":758},"citation_firstpage","1227864",{"hid":760,"name":760,"content":761},"citation_language","English",{"hid":763,"name":763,"content":537},"citation_title",{"hid":765,"name":765,"content":766},"citation_keywords","breast cancer; ovarian cancer; BRCA1; BRCA2; germline mutation",{"hid":768,"name":768,"content":542},"citation_abstract",{"hid":770,"name":770,"content":551},"citation_article_type",{"hid":772,"name":772,"content":773},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/pdf",{"hid":775,"name":775,"content":776},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1227864/xml",{"hid":778,"name":778,"content":779},"citation_fulltext_world_readable","yes",{"hid":781,"name":781,"content":782},"citation_online_date","2023/07/27",{"hid":784,"name":784,"content":785},"citation_publication_date","2023/08/17",{"hid":787,"name":788,"content":789},"citation_author_0","citation_author","Ferreyra, Yomali ",{"hid":791,"name":792,"content":793},"citation_author_institution_0","citation_author_institution","Departamento de Bioingeniera, Universidad de Ingenieria y Tecnologa, Peru",{"hid":795,"name":788,"content":796},"citation_author_1","Rosas, Gina ",{"hid":798,"name":792,"content":799},"citation_author_institution_1","Departamento de Patologa, Insituto Nacional de Enfermedades Neoplsicas, Peru",{"hid":801,"name":788,"content":802},"citation_author_2","Cock-Rada, Alicia M. ",{"hid":804,"name":792,"content":805},"citation_author_institution_2","Departmento de Oncologa Mdica, Instituto de Cancerologa Las Amricas - Auna, Colombia",{"hid":807,"name":788,"content":808},"citation_author_3","Araujo, Jhajaira ",{"hid":810,"name":792,"content":811},"citation_author_institution_3","Centro de Investigacin Bsicas y traslacional, Peru",{"hid":813,"name":788,"content":814},"citation_author_4","Bravo, Leny ",{"hid":816,"name":792,"content":817},"citation_author_institution_4","Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Peru",{"hid":819,"name":788,"content":820},"citation_author_5","Doimi, Franco ",{"hid":822,"name":792,"content":823},"citation_author_institution_5","Oncogenomics, Auna, Peru",{"hid":825,"name":788,"content":826},"citation_author_6","Casas, Jhoysi ",{"hid":828,"name":792,"content":823},"citation_author_institution_6",{"hid":830,"name":788,"content":831},"citation_author_7","Clavo, Mara de los ngeles ",{"hid":833,"name":792,"content":834},"citation_author_institution_7","Facultad de Medicina Humana, Universidad Nacional San Luis Gonzaga, Peru",{"hid":836,"name":788,"content":837},"citation_author_8","Pinto, Joseph A. ",{"hid":839,"name":792,"content":811},"citation_author_institution_8",{"hid":841,"name":788,"content":842},"citation_author_9","Belmar-Lpez, Carolina ",{"hid":844,"name":792,"content":817},"citation_author_institution_9",{"hid":846,"name":846,"content":847},"dc.identifier","doi:10.3389/fonc.2023.1227864",[849,852,854,856,858],{"src":850,"body":13,"type":851,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":853,"body":13,"type":851,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":855,"body":13,"type":851,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":857,"body":13,"type":851,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1227864?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":859,"body":13,"type":851,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":861,"articleHubArticlesList":862,"canJournalHasArticleHub":367,"articleDoiList":863},{},[],[],{"title":19,"image":-1,"breadcrumbs":865,"linksCollection":866,"metricsCollection":868},[],{"total":388,"items":867},[],{"total":388,"items":869},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1227864?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>